

FORM 490, 1399 (3/2000)
(REV. 11/98)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371

0152.00391


U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR

09/743781

INTERNATIONAL APPLICATION NO.
PCT/US99/15947INTERNATIONAL FILING DATE
13 July 1999PRIORITY DATE CLAIMED
13 July 1998

TITLE OF INVENTION

MODULATION OF THE PHOSPHOLIPASE A2 PATHWAY AS A THERAPEUTIC

APPLICANT(S) FOR DO/EO/US
Daniel Paris et al.

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371 (c) (2))
 - a. ☒ is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ has been transmitted by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. ☒ A copy of the International Search Report (PCT/ISA/210).
8. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
 - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ have been transmitted by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☒ have not been made and will not be made.
9. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
10. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).
11. ☒ A copy of the International Preliminary Examination Report (PCT/IPEA/409).
12. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).

Items 13 to 20 below concern document(s) or information included:

13. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
14. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
15. ☒ A **FIRST** preliminary amendment.
16. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
17. ☐ A substitute specification.
18. ☐ A change of power of attorney and/or address letter.
19. ☒ Certificate of Mailing by Express Mail
20. ☐ Other items or information:

CERTIFICATE OF MAILING BY EXPRESS MAIL[®]

U.S. AIR MAIL Mailing Label Number

1-11-01

1. This document is being deposited with the United States Postal Service Express Mail[®] service under 37 CFR 1.40 (b) (1) and is being received by the addressee above and is in full compliance with the requirements of 37 CFR 1.40 (b) (1) and 37 CFR 1.40 (b) (2).

Box Patent Application
Mona M. Dewitt

(Signature of person mailing paper or tape)

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR 09/743781)		INTERNATIONAL APPLICATION NO. PCT/US99/15947		ATTORNEY'S DOCKET NUMBER 0152.00391	
--	--	--	--	---	--


21. The following fees are submitted: BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) : <input type="checkbox"/> Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO \$1,000.00 <input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$860.00 <input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$710.00 <input checked="" type="checkbox"/> International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$690.00 <input type="checkbox"/> International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4) \$100.00				CALCULATIONS PTO USE ONLY	
ENTER APPROPRIATE BASIC FEE AMOUNT =				\$690.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than months from the earliest claimed priority date (37 CFR 1.492 (e)). <input type="checkbox"/> 20 <input type="checkbox"/> 30				\$0.00	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	21 - 20 =	1	x \$18.00	\$18.00	
Independent claims	5 - 3 =	2	x \$80.00	\$160.00	
Multiple Dependent Claims (check if applicable). <input type="checkbox"/>				\$0.00	
TOTAL OF ABOVE CALCULATIONS =				\$868.00	
Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28) (check if applicable). <input checked="" type="checkbox"/>				\$434.00	
SUBTOTAL =				\$434.00	
Processing fee of \$130.00 for furnishing the English translation later than months from the earliest claimed priority date (37 CFR 1.492 (f)). <input type="checkbox"/> 20 <input type="checkbox"/> 30 +				\$0.00	
TOTAL NATIONAL FEE =				\$434.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable). <input type="checkbox"/>				\$0.00	
TOTAL FEES ENCLOSED =				\$434.00	
				Amount to be: refunded	\$
				charged	\$

☒ A check in the amount of **\$434.00** to cover the above fees is enclosed.
☐ Please charge my Deposit Account No. _____ in the amount of _____ to cover the above fees.
 A duplicate copy of this sheet is enclosed.
☒ The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment to Deposit Account No. **11-1449** A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Amy E. Rinaldo
 Kohn & Associates
 30500 Northwestern Hwy.
 Suite 410
 Farmington Hills, Michigan 48334
 (248) 539-5050
 FAX (248) 539-5055


 SIGNATURE
 Amy E. Rinaldo
 NAME
 45,791
 REGISTRATION NUMBER
 January 11, 2001
 DATE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: University of South Florida

International Application No. PCT/US99/15947

International Filing Date: 13 July 1999

For: MODULATION OF THE PHOSPHOLIPASE A2
PATHWAY AS A THERAPEUTIC

Attorney Docket No. 0152.00391

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Please preliminarily amend the above-captioned patent application
prior to examination on the merits as follows:

IN THE SPECIFICATION:

Page 1, after the Title, please insert the following section:

--CROSS REFERENCE TO RELATED APPLICATIONS

This patent application is a National Phase concerning a filing under
35 U.S.C. 371, claiming the benefit of priority of U.S. Provisional Application Serial
No. 60/092,570, filed July 13, 1998, which is incorporated herein by reference.--

REMARKS

The above amendment adds no new matter and is merely made to more accurately describe and claim the invention, to claim benefit of priority, and to eliminate multiple claim dependencies.

It is respectfully submitted that the application is now in condition for allowance, which allowance is respectfully requested.

Respectfully submitted,

KOHN & ASSOCIATES



Amy E. Rinaldo
Registration No. 45,791
30500 Northwestern Hwy. Ste. 410
Farmington Hills, Michigan 48334
(248) 539-5050

Dated: January 11, 2001

CERTIFICATE OF MAILING

Express Mail Mailing Label No.: EL 405 596 965 US
Date of Deposit: January 11, 2001

I hereby certify that this correspondence is being deposited with the United States Postal Service as "Express Mail Post Office To Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, BOX PATENT APPLICATION.



Marie M. DeWitt

**VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY
STATUS (37 CFR 1.9(f) AND 1.27 (d)) - NONPROFIT ORGANIZATION**

Docket No.
0152.00391

Serial No.

Filing Date

Patent No.

Issue Date

Applicant/ **Daniel Paris et al.**
Patentee:

Invention: **MODULATION OF THE PHOSPHOLIPASE A2 PATHWAY AS A THERAPEUTIC**

I hereby declare that I am an official empowered to act on behalf of the nonprofit organization identified below:

NAME OF ORGANIZATION: University of South Florida

ADDRESS OF ORGANIZATION: 4202 East Fowler Avenue
FAO 126
Tampa, FL 33620-7900
TYPE OF NONPROFIT ORGANIZATION:

- ☒ University or other Institute of Higher Education
- ☐ Tax Exempt under Internal Revenue Service Code (26 U.S.C. 501(a) and 501(c)(3))
- ☐ Nonprofit Scientific or Educational under Statute of State of The United States of America
Name of State: _____ Citation of Statute: _____
- ☐ Would Qualify as Tax Exempt under Internal Revenue Service Code (26 U.S.C. 501(a) and 501(c)(3)) if Located in The United States of America
- ☐ Would Qualify as Nonprofit Scientific or Educational under Statute of State of The United States of America if Located in The United States of America
Name of State: _____ Citation of Statute: _____

I hereby declare that the above-identified nonprofit organization qualifies as a nonprofit organization as defined in 37 C.F.R. 1.9(e) for purposes of paying reduced fees to the United States Patent and Trademark Office regarding the invention described in:

- ☒ the specification to be filed herewith.
- ☐ the application identified above.
- ☐ the patent identified above.

I hereby declare that rights under contract or law have been conveyed to and remain with the nonprofit organization with regard to the above identified invention.

If the rights held by the above-identified nonprofit organization are not exclusive, each individual, concern or organization having rights to the invention is listed on the next page and no rights to the invention are held by any person, other than the inventor, who could not qualify as an independent inventor under 37 CFR 1.9(c) or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d) or a nonprofit organization under 37 CFR 1.9(e).

Each person, concern or organization to which I have assigned, granted, conveyed, or licensed or am under an obligation under contract or law to assign, grant, convey, or license any rights in the invention is listed below:

- ☒ no such person, concern or organization exists.
☐ each such person, concern or organization is listed below.

FULL NAME _____
 ADDRESS _____

☐ Individual ☐ Small Business Concern ☐ Nonprofit Organization

FULL NAME _____
 ADDRESS _____

☐ Individual ☐ Small Business Concern ☐ Nonprofit Organization

FULL NAME _____
 ADDRESS _____

☐ Individual ☐ Small Business Concern ☐ Nonprofit Organization

FULL NAME _____
 ADDRESS _____

☐ Individual ☐ Small Business Concern ☐ Nonprofit Organization

Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities. (37 CFR 1.27)

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

NAME OF PERSON SIGNING: **Kenneth G. Preston**

TITLE IN ORGANIZATION: **Director**

ADDRESS OF PERSON SIGNING: **Division of Patents & Licensing**

University of South Florida

4202 East Fowler Avenue

FAO 126

Tampa, Florida 33620-7900

SIGNATURE: _____ DATE: _____

PTO/PCT Rec'd 11 JAN 2001

MODULATION OF THE PHOSPHOLIPASE A2 PATHWAY
AS A THERAPEUTIC

BACKGROUND OF THE INVENTION

1. FIELD OF THE INVENTION

The present invention relates to methods and compositions to reduce the neuronal cell death associated with the pro-inflammatory pathway and vasoactivity. More specifically, the present invention relates to specific modulation of signal transduction pathways, such as the sPLA₂/MAPK/cPLA₂/AA/LOX/COX pathway, to reduce the pro-inflammatory response that leads to an enhanced production of eicosanoids.

2. DESCRIPTION OF RELATED ART

The protein β -amyloid (A4, A β , A β ₁₋₃₉₋₄₂) has long been central to the neuropathology of Alzheimer's disease (Glenner and Wong, 1984). However, its role in the disease process of Alzheimer's disease and other diseases, as well as its mechanism of action, remains in dispute.

It is undisputed that β -amyloid protein is a major component of the neuritic plaques which, along with the neurofibrillary tangles, provide the neuropathological

diagnostic markers for Alzheimer's disease (Mattson, 1995; Vantner et al., 1991). It is also deposited around cerebral blood vessels in Alzheimer's disease (Scholz, 1938; Mandybur, 1975; Vinters, 1987).

The sequence for α -amyloid is known (Glenner et al. 1984).

Emphasis has been on Alzheimer's being a neurological disease, not a vascular disease.

It has been suggested in Alzheimer's disease pathogenesis that β -amyloid has putative neurotoxic properties. However, there has been no consistent detection of such neurotoxic effects and there are conflicting reports (Price et al. 1992).

Referring to Teller et al. (1996), deposits of insoluble fibrils of amyloid α -peptide (A) in the brain is a prominent neuropathological feature of all forms of Alzheimer's Disease (AD) regardless of the genetic predisposition of the subject. In addition to the deposition of A in senile plaques and neurofibrillary tangles, vascular amyloid deposition resulting in cerebral amyloid angiopathy is a hallmark of AD and related disorders such as Down's Syndrome. The abnormal accumulation of A is due to either over expression or altered processing of amyloid precursor protein (APP), a transmembrane glycoprotein. Soluble A containing forty amino acids (A₄₀) and to a lesser degree the peptide with forty-two amino acids (A₄₂) forms the core of the amyloid deposits. The APP gene is highly conserved across different species and APPmRNA has been detected in all tissues, suggesting a normal physiologic role for A. The cellular origin of A

deposited in the brain or cerebral blood vessels in AD or its precise role in the neurodegenerative process has not been established.

Epidemiologic studies have demonstrated that anti-inflammatory therapy may be useful in the treatment of AD since a lower than expected prevalence or delayed onset of AD is apparent in patient populations using non-steroidal anti-inflammatory drugs (McGeer and McGeer, 1999; Rogers et al., 1993; and Stewart et al., 1997). Although the initiating event leading to AD-associated neuroinflammation remains speculative, the occurrence of immune system proteins, activated microglia and astrocytes among perivascular senile plaques suggests a possible involvement of A β in the induction of this inflammatory process (Coria et al., 1993; Griffin et al., 1995; Itagaki et al., 1989; Lue et al., 1996).

Arachidonic acid (AA) release and production of eicosanoids are prerequisites for inflammation, and phospholipase A₂ (PLA₂s) are key enzymes that initiate the AA cascade, which leads to the generation of multiple eicosanoid products during both acute and chronic inflammation. PLA₂ activity has been shown to be elevated in disease states with a strong inflammatory component, such as rheumatoid arthritis and septic shock (Basso et al., 1990; Morita et al., 1995). PLA₂s can be subdivided into several groups based upon their structures and enzymatic characteristics (Dennis, 1997). Secretory PLA₂s (sPLA₂s) are low molecular mass (~14 kDa) enzymes that require a millimolar concentration of Ca²⁺ to exert their enzymatic action and have little fatty acid selectivity when assayed *in vitro* (Tischfield, J.A., 1997). Cytosolic PLA₂ (cPLA₂) is an ubiquitously distributed 85-kDa enzyme, and requires

a submicromolar concentration of Ca^{2+} for effective hydrolysis of its substrate, AA-containing glycerophospholipids (Clark et al., 1991). The N-terminal CALB domain is responsible for Ca^{2+} -dependent translocation of cPLA₂ from the cytosol to perinuclear and endoplasmic reticular membranes (Glover et al., 1995), where several eicosanoid-generating enzymes, such as the two cyclooxygenases (COX-1 and COX-2) and 5-lipoxygenase (5-LOX), are located (Morita et al., 1995). Cytosolic PLA₂ has multiple phosphorylation sites, among which the mitogen-activated protein kinase-directed site (Ser⁵⁰⁵) is the most critical for its activation (Lin et al, 1993).

Abnormal phospholipid metabolism has been found in AD brains, where changes were reported in concentrations of membrane phospholipids, their precursors, and catabolites, which could be evidence for abnormal PLA₂ activity in these patients (Farooqui et al., 1997; Nitsch et al., 1992). Moreover, marked increases have been reported in the levels of prostaglandins and lipid peroxides in AD brain (Iwamoto et al., 1989; Jeandel et al., 1989), both products of PLA₂ activity. Elevated cPLA₂ immunoreactivity (Stephenson et al., 1996) has been reported in association with amyloid deposits in the cortex of AD brain, supporting the hypothesis that there is an active inflammatory process occurring in AD. Furthermore, soluble $\text{A}\beta_{1-42}$ (in the pM to nM range) in a cell-free system has been shown to activate sPLA₂ (Lehtonen et al., 1996), suggesting that $\text{A}\beta$ may exert its effects either on the substrate or directly on sPLA₂.

Using intact rat aortae in a tissue bath system, it was previously reported that $\text{A}\beta$ peptides are vasoactive, and suggested that this vasoactivity could contribute to

Alzheimer's pathology by reducing cerebral blood flow (Thomas et al., 1996). It has also been shown that A β peptides are able to enhance the vasoconstriction induced by endothelin-1 (ET-1), a potent endogenous vasoconstrictor responsible for control of cerebral vasotonus (Crawford et al., 1998) via a mechanism independent of reactive oxygen species (Paris et al., 1998). Furthermore, it was demonstrated that intra-arterial infusion of A β results in reduced cerebral blood flow in vivo (Suo et al., 1998), and similar impaired cerebral blood flow has been shown in transgenic mice which endogenously overproduce A β peptides (Iadecola, et al., 1999).

It would therefore be useful to detail the molecular mechanisms responsible for A β 's enhancement of ET-1-induced vasoconstriction. It would also be useful to develop a method and pharmaceutical composition for counteracting such a pathway.

SUMMARY OF THE INVENTION

According to the present invention, there is provided a method of modifying vasoactivity by regulating a soluble A β pro-inflammatory pathway. Also provided is a method of treating patients with vascular disease by modifying an intracellular soluble A β pro-inflammatory pathway. Also provided is a method of modifying inflammatory reactions in microglia and neurons by regulating a soluble A β pro-inflammatory pathway. A pharmaceutical composition consisting essentially of an effective amount of an A β pro-inflammatory pathway regulator in a pharmaceutically effective carrier is also provided.

DESCRIPTION OF THE DRAWINGS

Other advantages of the present invention will be readily appreciated as the same becomes better understood by reference to the following detailed description when considered in connection with the accompanying drawings wherein:

Figure 1 is a graph showing the dose response curve showing $A\beta_{1-40}$ vasoactivity;

Figure 2 is a bar graph illustrating that $A\beta$ induces a long-lasting vasoconstriction;

Figure 3 is a graph showing the interaction among melittin, $A\beta$, and ET-1 on vasoconstriction;

Figure 4 is a graph showing the interaction among mastoparan, $A\beta$, and ET-1 on vasoconstriction;

Figure 5 is a graph showing the interaction among isotetrandrine, $A\beta$, and ET-1 on vasoconstriction;

Figure 6 is a graph showing the interaction among pancreatic $sPLA_2$ (type I), $A\beta$, and ET-1 on vasoconstriction;

Figure 7 is a graph showing the interaction among oleyloxyethylphosphocholine, $A\beta_{1-40}$, and ET-1 on vasoconstriction;

Figure 8 is a graph showing the effect of $sPLA_2$ (type II) inhibition on $A\beta$ induced vasoactivity;

Figure 9 is a graph showing the effect of cPLA₂ inhibition on A β induced vasoactivity;

Figure 10 is a graph showing the effect of Ca₂⁺-independent PLA₂ (type VI) inhibition on A β induced vasoactivity;

Figure 11 is a graph showing the effect of COX-2 inhibition on A β enhancement of ET-1 induced vasoconstriction;

Figure 12 is a graph showing the interaction among MK-886, and A β ₁₋₄₀ and ET-1 on vasoconstriction;

Figure 13 is a graph showing the effect of RHC80267 on A β enhancement of ET-1 induced vasoconstriction;

Figure 14 is a graph showing the effect of DHE on A β enhancement of ET-1 induced vasoconstriction;

Figure 15 is a graph showing the effect of bisindolylmaleimide I on A β enhancement of ET-1 induced vasoconstriction;

Figure 16 is a graph showing the effect of MEK1/2 inhibition on A β ₁₋₄₀ enhancement of ET-1 induced vasoconstriction;

Figure 17 is a graph showing the effect of MEK1/2 inhibition on A β ₁₋₄₂ enhancement of ET-1 induced vasoconstriction;

Figure 18 is a graph showing the effect of MEK1/2 inhibition on sPLA₂ enhancement of ET-1 induced vasoconstriction;

Figure 19 is a graph showing the effect of p38MAPK inhibition on A β enhancement of ET-1 induced vasoconstriction;

Figure 20 is a graph showing the effect of sPLA₂ on [³H]AA release;

Figure 21 is a graph showing the effect of cPLA₂ inhibition on [³H]AA release by A β ;

Figure 22 is a graph showing the effect of MEK1/2 inhibition on [³H]AA release induced by A β ;

Figure 23 is a graph showing that A β -induced microglial LTB₄ release is blocked by inhibiting elements of the sPLA₂/AA/5-LOX/COX-2 pathway;

Figure 24 is a graph showing that sPLA₂ and A β induce [³H]AA release in N9 microglia;

Figure 25 is a graph showing that the soluble A β peptides induce [³H]AA release in neuronal cells; and

Figure 26 is a graph showing that the activation of p38 MAPK by soluble A β peptides in neuronal cells.

DETAILED DESCRIPTION OF THE INVENTION

Generally, the present invention relates to a method and pharmaceutical composition for modifying the soluble A β pro-inflammatory pathway. Also provided is a method for treating patients with vascular disease (i.e. cerebral amyloid angiopathy, vascular amyloidosis, etc.) by modifying the intracellular A β pro-inflammatory pathway. More specifically, the present invention provides a method and composition for modifying the A β vasoactivity by antagonizing the sPLA₂/MAPK/cPLA₂/AA/LOX/COX pathway. Also provided is a method of modifying inflammatory reactions in microglia and neurons by regulating a soluble A β pro-inflammatory pathway.

It is generally thought that the Alzheimer A β peptides play an essential role in the pathogenesis of this disease, although the detailed mechanisms of neurodegeneration are not known. For instance, although deposits of A β are required for neuropathological diagnosis of AD by definition, this does not necessarily infer that the deposited form is pathologic. It is quite possible that soluble forms of A β are pathogenic. Soluble A β peptides display vasoactive properties, for instance by significantly enhancing the vasoconstriction elicited by an endogeneous cerebral vasoconstriction, endothelin-1 (ET-1). This phenomenon is exploited in the present invention and utilized a vessel bath system in order to delineate the specific signal transduction pathway leading to A β vasoactivity as shown in the Example herein.

The data demonstrate that A β (1-40) and A β (1-42) mediate vasoactivity by an activation of PLA₂ through a stimulation of G-protein. The arachidonic acid product of

PLA2 is metabolized essentially through two distinct pathways: cyclooxygenases and lipxygenases. It is shown herein that the vasoactive properties of A β (1-40) and A β (1-42) are mediated by 5-lipxygenase and by cyclo-oxygenase-2.

As an extension of these findings in a non-vascular system, there is shown that addition of A β (1-40) to microglial cells stimulates leukotriene B4 release (a major metabolite of 5-lipxygenase) and AA release. Additionally, soluble A β peptides promote AA release from cultured neurons (NGF- β differentiated PC12 cells). Furthermore, drugs which oppose the pathway activated by soluble A β peptides oppose soluble A β -induced microglial LTB4 release. Taken together, these data show that soluble A β (1-40) and A β (1-42) induce a pro-inflammatory response pathway that leads to an enhanced production of AA and eicosanoids.

These findings demonstrate that the effect of A β can be modulated by manipulating specific signal transduction pathways providing the basis for novel therapeutic interventions. Specifically, drugs which modulate the phospholipase A2/arachidonic acid/5-lipxygenase/cyclo-oxygenase-2 (PLA2/AA/5-LOX/COX-2) pro-inflammatory pathway are used in the practice of the present invention. Any drug that specifically opposes activation of the PLA2/AA/5-LOX/COX-2 pathway reducing A β -induced vasoconstriction and hypoperfusion can be utilized in the practice of the invention.

The pharmaceutical compositions or drugs include, but are not limited to, antagonists of PLA2 stimulation such as those that oppose G-protein activation of PLA2.

0152.00343

They can include compositions which directly inhibit PLA2 or drugs which inhibit 5-LOX or COX-2. Isotetrandrine is a specific G-protein inhibitor which can be used.

The present invention further provides for the administration of antagonists/drugs of the PLA2/AA/5-LOX/COX-2 pro-inflammatory pathway in the treatment of... hypertension which is genetically linked to PLA2 (Frossard, PM, and Lestringant, GG (1995)), and genetically linked to G_i-protein (Siffert et al.) Further, the present invention provides for the administration of antagonists/drugs of the PLA2/AA/5-LOX/COX-2 pathway/cascade in the treatment of vasospasm associated with severe post-traumatic head injury.

The present invention therefore provides therapeutics which modulate (such as antagonists) signal transduction pathways, such as PLA2/AA/5-LOX/COX-2, to reduce the pro-inflammatory response that leads to an enhanced production of leukotrienes. The term antagonist or antagonizing is used in its broadest sense. Antagonism can include any mechanism or treatment which results in inhibition, inactivation, blocking or reduction of the signal pathway. For example, the antagonizing step can include blocking PLA-2 activation.

The compound of the present invention is administered and dosed in accordance with good medical practice, taking into account the clinical condition of the individual patient, the site and method of administration, scheduling of administration, patient age, sex, body weight and other factors known to medical practitioners. The pharmaceutically "effective amount" for purposes herein is thus determined by such considerations as are known in the art. The amount must be effective to achieve improvement

0152.00343

including but not limited to improved survival rate or more rapid recovery, or improvement or elimination of symptoms and other indicators as are selected as appropriate measures by those skilled in the art.

In the method of the present invention, the compound of the present invention can be administered in various ways. It should be noted that it can be administered as the compound or as pharmaceutically acceptable salt and can be administered alone or as an active ingredient in combination with pharmaceutically acceptable carriers, diluents, adjuvants and vehicles. The compounds can be administered orally, subcutaneously or parenterally including intravenous, intraarterial, intramuscular, intraperitoneally, and intranasal administration as well as intrathecal and infusion techniques. Implants of the compounds are also useful. The patient being treated is a warm-blooded animal and, in particular, mammals including man. The pharmaceutically acceptable carriers, diluents, adjuvants and vehicles as well as implant carriers generally refer to inert, non-toxic solid or liquid fillers, diluents or encapsulating material not reacting with the active ingredients of the invention.

It is noted that humans are treated generally longer than the mice or other experimental animals exemplified herein which treatment has a length proportional to the length of the disease process and drug effectiveness. The doses may be single doses or multiple doses over a period of several days, but single doses are preferred.

The doses may be single doses or multiple doses over a period of several days. The treatment generally has

a length proportional to the length of the disease process and drug effectiveness and the patient species being treated.

When administering the compound of the present invention parenterally, it will generally be formulated in a unit dosage injectable form (solution, suspension, emulsion). The pharmaceutical formulations suitable for injection include sterile aqueous solutions or dispersions and sterile powders for reconstitution into sterile injectable solutions or dispersions. The carrier can be a solvent or dispersing medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils.

Proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Nonaqueous vehicles such as cottonseed oil, sesame oil, olive oil, soybean oil, corn oil, sunflower oil, or peanut oil and esters, such as isopropyl myristate, may also be used as solvent systems for compound compositions. Additionally, various additives which enhance the stability, sterility, and isotonicity of the compositions, including antimicrobial preservatives, antioxidants, chelating agents, and buffers, can be added. Prevention of the action of microorganisms can be ensured by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, and the like. In many cases, it will be desirable to include isotonic agents, for example, sugars, sodium chloride, and the like. Prolonged absorption of the injectable pharmaceutical form can be brought about by the use of agents delaying absorption, for

example, aluminum monostearate and gelatin. According to the present invention, however, any vehicle, diluent, or additive used would have to be compatible with the compounds.

Sterile injectable solutions can be prepared by incorporating the compounds utilized in practicing the present invention in the required amount of the appropriate solvent with various of the other ingredients, as desired.

A pharmacological formulation of the present invention can be administered to the patient in an injectable formulation containing any compatible carrier, such as various vehicle, adjuvants, additives, and diluents; or the compounds utilized in the present invention can be administered parenterally to the patient in the form of slow-release subcutaneous implants or targeted delivery systems such as monoclonal antibodies, vectored delivery, iontophoretic, polymer matrices, liposomes, and microspheres. Examples of delivery systems useful in the present invention include: 5,225,182; 5,169,383; 5,167,616; 4,959,217; 4,925,678; 4,487,603; 4,486,194; 4,447,233; 4,447,224; 4,439,196; and 4,475,196. Many other such implants, delivery systems, and modules are well known to those skilled in the art.

A pharmacological formulation of the compound utilized in the present invention can be administered orally to the patient. Conventional methods such as administering the compounds in tablets, suspensions, solutions, emulsions, capsules, powders, syrups and the like are usable. Known techniques which deliver it orally or intravenously and retain the biological activity are preferred.

In one embodiment, the compound of the present invention can be administered initially by intravenous injection to bring blood levels to a suitable level. The patient's levels are then maintained by an oral dosage form, although other forms of administration, dependent upon the patient's condition and as indicated above, can be used. The quantity to be administered will vary for the patient being treated and will vary from about 100 ng/kg of body weight to 100 mg/kg of body weight per day and preferably will be from 10 µg/kg to 10 mg/kg per day

The above discussion provides a factual basis for the use of methods and pharmaceutical compositions for modifying vasoactivity by regulating the soluble A β pro-inflammatory pathway. The methods used with and the utility of the present invention can be shown by the following non-limiting examples and the accompanying figures.

EXAMPLES:

GENERAL METHODS:

General methods in molecular biology: Standard molecular biology techniques known in the art and not specifically described are generally followed as in Sambrook et al., *Molecular Cloning: A Laboratory Manual*, Cold Springs Harbor Laboratory, New York (1989, 1992), and in Ausubel et al., *Current Protocols in Molecular Biology*, John Wiley and Sons, Baltimore, Maryland (1989). Polymerase chain reaction (PCR) is carried out generally as in PCR

Protocols: A Guide To Methods And Applications, Academic Press, San Diego, CA (1990). Reactions and manipulations involving other nucleic acid techniques, unless stated otherwise, are performed as generally described in Sambrook et al., 1989, *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, and methodology as set forth in United States patents 4,666,828; 4,683,202; 4,801,531; 5,192,659 and 5,272,057 and incorporated herein by reference. In-situ (In-cell) PCR in combination with Flow Cytometry can be used for detection of cells containing specific DNA and mRNA sequences (Testoni et al, 1996, Blood 87:3822.)

General methods in immunology: Standard methods in immunology known in the art and not specifically described are generally followed as in Stites et al.(eds), *Basic and Clinical Immunology* (8th Edition), Appleton & Lange, Norwalk, CT (1994) and Mishell and Shiigi (eds), *Selected Methods in Cellular Immunology*, W.H. Freeman and Co., New York (1980).

Immunoassays

In general, ELISAs are the preferred immunoassays employed to assess a specimen. ELISA assays are well known to those skilled in the art. Both polyclonal and monoclonal antibodies can be used in the assays. Where appropriate other immunoassays, such as radioimmunoassays (RIA) can be used as are known to those in the art. Available immunoassays are extensively described in the patent and scientific literature. See, for example, United States patents 3,791,932; 3,839,153; 3,850,752; 3,850,578; 3,853,987; 3,867,517; 3,879,262; 3,901,654; 3,935,074; 3,984,533; 3,996,345; 4,034,074; 4,098,876; 4,879,219; 5,011,771 and 5,281,521 as well as Sambrook et al,

Molecular Cloning: A Laboratory Manual, Cold Springs Harbor, New York, 1989

EXAMPLE 1

The following example demonstrates that soluble Alzheimer's β -amyloid peptides mediate vasoactivity through a pro-inflammatory pathway, the phospholipase A2/arachidonic acid/5-lipoxygenase/cyclo-oxygenase-2 cascade. Furthermore, this example shows that blocking specific target molecules on this pathway oppose the effect of soluble A β peptides (1-40 and 1-42) in the vasculature.

Materials and Methods

The compounds used in vasoactivity assays include: Porcine pancreatic PLA₂ (sPLA₂), melittin, mastoparan and ET-1 were purchased from Sigma. Isotetrandrine, MK-886, RHC-80267, diacylglycerol (DAG), oleyloxyethylphosphocholine (oleyllox.), bisindolylmaleimide I (bisindol.), PD98059, SB202190, methyl arachidonyl fluophosphonate (MAFP), quercetin, haloenol lactone suicide substrate (HELSS), AACOCF3 and NS-398 were obtained from Calbiochem. A β_{1-40} and A β_{1-42} were obtained from QCB. MK-886, RHC-80267, DAG, bisindol., PD98059, SB202190, MAFP, quercetin, HELSS, AACOCF3, NS-398, A β_{1-40} and A β_{1-42} and oleylox. were dissolved in DMSO, whereas melittin, mastoparan and ET-1 were dissolved in HPLC grade water, and sPLA₂ was dissolved in Kreb's buffer.

Vessel experiments. Freshly dissected aortae were prepared from normal male Sprague-Dawley rats (7-8 months

old, purchased from Zivic Miller, Zelienople, PA) as previously described by Paris et al, Exp Neurol 1998 and Exp Neurol 1999. Rat aortae were segmented into rings and suspended in Kreb's buffer on hooks connected to a tensiometer linked to a MacLab system. Aortic rings were equilibrated for 2 hours, in 7 mL tissue baths containing Kreb's buffer oxygenated with 95% O₂ : 5% CO₂, and thermoregulated to 37°C. A baseline tension of 2 g was applied to each ring, and the first set of aortic rings was pretreated with the various compounds named above either alone or in combination with A β peptides. After 5 minutes of incubation in the presence or absence of A β , this first set of vessels was subjected to a dose range of ET-1 (from 1 nM to 5 nM). A second set of vessels was treated with 1 μ M of A β peptides prior to the addition of ET-1. A third set (control) received only ET-1 treatment. Each ET-1 dose was added only after the constriction response to the previous dose had reached a plateau. In all cases the means \pm 1 standard error (SE) of the percentage vasoconstriction increase over baseline were determined for each dose of ET-1 used.

Measurement of [³H]AA release in intact rat aortae. Aortic rings (1.5 mm long) were placed in 1 mL of physiological saline solution (PSS, containing 130 mM NaCl, 5 mM KCl, 1.5 mM CaCl₂, 1.2 mM MgCl₂, 10 mM HEPES, and 10 mM glucose adjusted to pH 7.2 with NaOH) and incubated with 2.5 μ Ci of [³H]AA (specific activity of 91.8 Ci/mmol) for 24 h at 4°C. Rat aortae were subsequently washed in 50 mL of Kreb's buffer and then subjected to the vasoactivity assay. Initial background [³H]AA release was determined following 30 min of equilibration for each aortic ring prior to treatment by removing 200 μ L of Kreb's buffer (total volume

of 7 mL each) from each bath, and measuring radioactivity (in cpm) after the addition of 1 mL of scintillant (EcoLume, ICN Inc., CA) using a liquid scintillation counter (1209 Rackbeta, WALLAC Inc., MD). Subsequently, aortic rings were treated with $sPLA_2$ alone or $A\beta_{1-40}$ (1 μM) in the presence or absence of a MEK1/2 inhibitor (PD 98059) or a $cPLA_2$ inhibitor (AACOCF3) for 5 min, or went untreated for the same length of time (control). Quantification of [3H]AA release was then performed as described above. All aortic rings were then subjected to a dose range of ET-1 (1, 2.5, and 5 nM), and radioactivity was measured 5 min after the first dose of ET-1 (1 nM), and 20 min after the second (2.5 nM) and third (5 nM) doses of ET-1. Radioactivity incorporated into each ring was determined by placing the aortic ring in 1 mL of scintillant and assaying as described above. Results are expressed as the means \pm 1 SE of the percentage of [3H]AA incorporated for each aortic ring $[(^3H)AA \text{ released} - (^3H)AA \text{ initial background}] / \text{incorporated } (^3H)AA$.

Statistical analysis. Analysis of variance (ANOVA) was used to analyze the data, with post-hoc comparisons of means carried out where appropriate by Sheffe's or Bonferonni's methods. As previously described (Paris et al., Neurosci Lett, 1998), a significant interactive term by ANOVA was taken as evidence that both drug x and $A\beta$ are modulating a common signal transduction pathway. However, if the effect of drug x and $A\beta$ was simply additive (or subtractive), this suggested modulation of independent transduction pathways. Levene's test for equality of variance followed by t-test for independent samples was used for single mean comparisons. Alpha levels

were set at 0.05 for all analyses. Analyses were performed using SPSS for Windows release 9.5.

Results

Characteristics of A β vasoactivity

It has previously been shown that freshly solubilized A β_{1-40} or A β_{1-42} increase the magnitude of constriction induced by ET-1 in isolated mammalian vessels, to a similar extent (Crawford et al., 1998). High levels of circulating A β_{1-42} have been observed in AD patients, ranging from 30 to 150 nM (mean of approximately 50 nM), and this is approximately 6 times higher than the level of A β found in non-demented controls (Lambeau et al., 1994). Similar doses of freshly solubilized A β enhance ET-1-induced vasoconstriction (Figure 1). Interestingly, A β does not only increase the magnitude of contraction induced by ET-1, but also enhances the sustained phase of ET-1-induced vasoconstriction (Figure 2). As with freshly solubilized A β enhancement of ET-1-induced vasoconstriction, this sustained constriction event induced is observed with doses as low as 50 nM. Long-lasting vasoconstriction induced by A β is evident with other vasoconstrictors, such as phenylephrine or a thromboxane A2 analogue (U-46619), indicating that long-lasting vasoconstriction is not specific to the vasoconstrictor used.

More specifically, Figure 1 shows the dose-response curve showing A β_{1-40} vasoactivity. Certain aortic rings were treated with a dose range of A β_{1-40} 5 minutes prior to the addition of a dose range of ET-1. Results are expressed as the mean \pm 1 SE of the percentage

vasoconstriction increase over baseline. ANOVA revealed significant main effects of ET-1 dose ($p < .001$), A β dose ($p < .001$), and an interactive term between them ($p < .001$). One-way ANOVA across ET-1 doses revealed significant between-groups differences ($p < .001$), and post-hoc comparison across the 2.5 nM and 5 nM doses of ET-1 showed a significant difference between the 50 nM dose of A β and the A β -free condition ($p = .001$).

Figure 2 shows that A β induces a long-lasting vasoconstriction. Certain aortic rings were treated with 1 μ M of A β_{1-40} or untreated (control) 5 minutes prior to the addition of a dose range of ET-1 (1, 2.5, and 5 nM). Following the 5 nM dose of ET-1, maximum tension was taken as the $t = 0$ time point [and standardized to 100% both in control ($n=8$) and A β -treated vessels ($n=8$)], with vasotension assessed for each following minute until $t = 10$ minutes. ANOVA revealed significant main effects of A β ($p < .001$), time ($p < .001$), and an interaction between them ($p < .001$). Post-hoc t test for independent samples across time points revealed a significant difference ($p < .001$) between control and A β -treated rat aortae.

Effect of PLA₂ activation on A β vasoactivity

Melittin (a constituent of bee venom) and mastoparan (a component of wasp venom) are two small peptides (26 and 14 amino acid residues, respectively) known to specifically activate PLA₂ and to stimulate G-proteins (preferentially G_i and G_o; Gravitt et al., 1994; Kanemasa et al., 1992). Both of these peptides potentiate ET-1-induced vasoconstriction to a similar extent as A β , thus mimicking A β vasoactivity (Figures 3 and 4). Further,

when either of these peptides are added to vessels in conjunction with ET-1 and A β , there is observed a 3-way interactive term by ANOVA, suggesting that A β and melittin or A β and mastoparan act on the same pathway leading to enhancement of ET-1-induced vasoconstriction.

Specifically, Figure 3 shows the interaction among melittin, A β , and ET-1 on vasoconstriction. Certain aortic rings were treated with 1 μ M of freshly solubilized A β ₁₋₄₀, 1 μ M of melittin, melittin + A β , or untreated (control) 5 minutes prior to the addition of a dose range of ET-1. ANOVA showed significant main effects of ET-1 dose ($p < .001$), A β ($p < .001$) and melittin ($p < .001$), as well as significant interactive terms between ET-1 dose and either A β ($p < .001$) or melittin ($p < .05$). Furthermore, there was a significant interactive term among ET-1 dose, A β and melittin ($p < .01$). One-way ANOVA across ET-1 doses revealed significant between-groups differences ($p < .001$), and post-hoc testing showed significant differences between control and A β ($p < .001$), control and melittin ($p < .02$), and control and A β + melittin ($p < .01$), but not between A β and melittin ($p = .776$), or between A β and A β + melittin ($p = .989$).

Also, Figure 4 shows the interaction among mastoparan, A β , and ET-1 on vasoconstriction. Certain aortic rings were treated with 1 μ M of freshly solubilized A β ₁₋₄₀, 5 μ M of mastoparan, mastoparan + A β , or untreated (control) 5 minutes prior to the addition of a dose range of ET-1. ANOVA showed significant main effects of ET-1 dose ($p < .001$), A β ($p < .001$) and mastoparan ($p < .001$), as well as significant interactive terms between ET-1 dose and

either A β ($p = .01$) or mastoparan ($p < .001$). There was also a significant interactive term among ET-1 dose, A β and mastoparan ($p < .001$). One-way ANOVA across ET-1 doses revealed significant between-groups differences ($p < .001$), and post-hoc testing showed significant differences between control and A β ($p < .001$), control and mastoparan ($p = .001$), and control and A β + mastoparan ($p = .001$), but not between A β and mastoparan ($p = .940$), or between A β and A β + mastoparan ($p = .973$).

Effect of G-protein inhibition on A β vasoactivity

Both melittin and mastoparan are known to be potent activators of G-proteins, mainly G $_i$ and G $_o$. The involvement of G $_o$ in A β vasoactivity was excluded, since the APP-derived peptide, APP657-676, a known stimulator of G $_o$ (Paris et al., 1998), was not able to modulate ET-1-induced vasoconstriction or to affect A β -vasoactivity. G $_i$ activation commonly results in an inhibition of adenylyl cyclase, and it has been shown that adenylyl cyclase does not mediate A β vasoactivity, since SQ-22536, a cell-permeable specific adenylyl cyclase inhibitor, does not have any effect on the vasoactive properties of A β (Rogers et al., 1993). Moreover, A β vasoactivity appears to be insensitive to pertussis toxin (PT), suggesting that it is independent of G $_i$. Interestingly, the activation of AA release induced by mastoparan is also completely insensitive to PT (Joyce-Brady et al., 1991), suggesting that mastoparan-induced PLA $_2$ activity occurs independently of G $_i$ activation, whereas inhibition of adenylyl cyclase by mastoparan is sensitive to PT. Isotetrandrine was also employed in the assay, which specifically inhibits G-protein activation of PLA $_2$, but not PLC or PLD (Walker et

al., 1995). When added in combination with A β , isotetrandrine partially blocked A β vasoactivity (Figure 5). Taken together, these data show that, while A β -vasoactivity is not significantly mediated via G $_i$ and G $_o$, it is dependent on the activation of the specific PLA $_2$ -coupled G-protein. These data further substantiate the involvement of PLA $_2$ s in the vasoactivity mediated by A β peptides.

Figure 5 specifically shows the interaction among isotetrandrine, A β , and ET-1 on vasoconstriction. Certain aortic rings were treated with 1 μ M of freshly solubilized A β_{1-40} , 25 μ M of isotetrandrine (isotet.), isotetrandrine + A β , or untreated (control) 5 minutes prior to the addition of a dose range of ET-1. ANOVA showed significant main effects of ET-1 dose ($p < .001$) and A β ($p < .001$), but not for isotetrandrine ($p = .245$). There were significant interactive terms between ET-1 dose and A β ($p < .001$), and among ET-1 dose, A β and isotetrandrine ($p < .001$). One-way ANOVA across ET-1 doses revealed significant between-groups differences ($p < .001$), and post-hoc testing showed significant differences between control and A β ($p < .001$), control and isotetrandrine ($p = .001$), control and A β + isotetrandrine ($p = .001$), between A β and isotetrandrine ($p < .05$), but not between isotetrandrine and A β + isotetrandrine ($p = .994$).

Determination of the contribution of specific PLA $_2$ isoforms to A β vasoactivity

In order to further substantiate the involvement of PLA $_2$ in A β vasoactivity, secretory porcine pancreatic PLA $_2$ (type I sPLA $_2$) was directly added into the vessel bath system. Porcine type I sPLA $_2$ displays a high homology

compared to mammalian type I sPLA₂ isoforms, especially human type I sPLA₂ (Han et al., 1997). Similar to A β peptides, type I sPLA₂ does not display intrinsic vasoactive properties, but is able to enhance the vasoconstriction induced by ET-1, mimicking the vasoactivity of A β (Figure 6). When added in combination with A β , there is observed an interactive term by ANOVA among ET-1, type I sPLA₂ and A β , suggesting that A β vasoactivity is mediated via stimulation of type I sPLA₂. Pretreatment of vessels with oleylox., a novel site-specific type I sPLA₂ inhibitor, completely blocks A β ₁₋₄₀ (Figure 7) and A β ₁₋₄₂ vasoactivity. Moreover, there is observed statistical interaction among ET-1, A β (1-40 or 1-42), and oleylox., suggesting that activity of type I sPLA₂ is needed to bring about A β vasoactivity. The potential contribution of type II sPLA₂ to A β -induced vasoactivity was also explored by using quercetin, a selective inhibitor of type II sPLA₂ (Lue et al., 1996), and aristolochic acid, which preferentially inhibits activity of type II sPLA₂ over type I sPLA₂. Quercetin is unable to block A β vasoactivity, suggesting that type II sPLA₂ does not mediate A β -vasoactivity (Figure 8). This is further substantiated by the fact that low doses of aristolochic acid (< 10 μ M) are unable to affect A β vasoactivity, whereas high doses (25 μ M) result in the partial blockade of the vasoactive properties of A β .

The possible involvement of cytosolic PLA₂ (type IV cPLA₂) in the vasoactive properties of A β was also investigated by using an irreversible inhibitor of cPLA₂, MAFP. Data show that MAFP completely inhibits A β -induced vasoactivity in a statistically interactive manner,

demonstrating that cPLA₂ activity is required to mediate A β vasoactivity (Figure 9). Furthermore, the contribution of calcium-independent PLA₂ (type VI) to the vasoactive properties of A β was investigated by incubating vessels with HELSS, a potent and irreversible inhibitor of type VI PLA₂. It was found that HELSS is unable to affect A β -induced vasoactivity, showing that type VI PLA₂ does not mediate the vasoactive properties of A β (Figure 10). Collectively, these data show that the vasoactive effect exerted by A β is specifically mediated by type I sPLA₂ and type IV cPLA₂.

Figure 6 shows the interaction among pancreatic sPLA₂ (type I), A β , and ET-1 on vasoconstriction. Certain aortic rings were treated with 1 μ M of freshly solubilized A β ₁₋₄₀, 1 U/mL of type I sPLA₂, PLA₂ + A β , or untreated (control) 5 minutes prior to the addition of a dose range of ET-1. There were significant main effects by ANOVA of ET-1 dose ($p < .001$), A β ($p < .001$) and PLA₂ ($p < .01$), as well as significant interactive terms between ET-1 dose and either A β ($p < .001$) or PLA₂ ($p < .001$). Furthermore, there was a significant interactive term among ET-1 dose, A β and PLA₂ ($p < .001$). One-way ANOVA across ET-1 doses revealed significant between-groups differences ($p < .01$), and post-hoc testing showed significant differences between control and A β ($p < .01$), control and PLA₂ ($p < .02$), and control and A β + PLA₂ ($p < .05$), but not between A β and PLA₂ ($p = .956$), or between A β and A β + PLA₂ ($p = .807$).

Additionally, Figure 7 shows the interaction among oleyloxyethylphosphocholine, A β ₁₋₄₀, and ET-1 on vasoconstriction. Certain aortic rings were treated with 1

μM of freshly solubilized $\text{A}\beta_{1-40}$, $1 \mu\text{M}$ of oleylox., oleylox. + $\text{A}\beta$, or untreated (control) 5 minutes prior to the addition of a dose range of ET-1. There were significant main effects by ANOVA of ET-1 dose ($p < .001$), $\text{A}\beta$ ($p < .001$), and of oleylox. ($p < .001$). There were also significant interactive terms between ET-1 dose and either $\text{A}\beta$ ($p < .001$) or oleylox. ($p < .001$), and among ET-1, $\text{A}\beta$ and oleylox. ($p < .001$). One-way ANOVA across ET-1 doses revealed significant between-groups differences ($p < .001$), and post-hoc testing showed significant differences between control and $\text{A}\beta$ ($p < .001$), and $\text{A}\beta$ and $\text{A}\beta$ + oleylox. ($p = .001$), but not between control and $\text{A}\beta$ + oleylox. ($p = .756$), control and oleylox. ($p = .886$), or oleylox. and $\text{A}\beta$ + oleylox. ($p = .992$). Similar results were observed with $\text{A}\beta_{1-42}$.

Figure 8 shows the effect of sPLA_2 (type II) inhibition on $\text{A}\beta$ -induced vasoactivity. Certain aortic rings were treated with $1 \mu\text{M}$ of freshly solubilized $\text{A}\beta_{1-40}$, $10 \mu\text{M}$ of quercetin, quercetin + $\text{A}\beta$, or untreated (control) 5 minutes prior to the addition of a dose range of ET-1. There were significant main effects by ANOVA of ET-1 dose ($p < .001$), $\text{A}\beta$ ($p < .001$), but not for quercetin ($p = .219$). There was also a significant interactive term between ET-1 dose and $\text{A}\beta$ ($p < .001$), but not among ET-1, $\text{A}\beta$ and quercetin ($p = .752$). One-way ANOVA across ET-1 doses revealed significant between-groups differences ($p < .001$), and post-hoc testing showed significant differences between control and $\text{A}\beta$ ($p = .001$), between control and $\text{A}\beta$ + quercetin ($p < .001$), between quercetin and $\text{A}\beta$ + quercetin

($p < .01$), but not between control and quercetin ($p = .919$), or $A\beta$ and $A\beta +$ quercetin ($p = .999$).

Also, Figure 9 shows the effect of $cPLA_2$ inhibition on $A\beta$ -induced vasoactivity. Certain aortic rings were treated with $1 \mu M$ of freshly solubilized $A\beta_{1-40}$, $1 \mu M$ of MAFF, $MAFF + A\beta$, or untreated (control) 5 minutes prior to the addition of a dose range of ET-1. There were significant main effects by ANOVA of ET-1 dose ($p < .001$), $A\beta$ ($p < .001$), but not for MAFF ($p < .001$). There were also significant interactive terms between ET-1 dose and $A\beta$ ($p < .01$), and among ET-1, $A\beta$ and MAFF ($p < .01$). One-way ANOVA across ET-1 doses revealed significant between-groups differences ($p < .001$), and post-hoc testing showed significant differences between control and $A\beta$ ($p < .001$), and $A\beta$ and $A\beta + MAFF$ ($p = .001$), but not between control and $A\beta + MAFF$ ($p = .743$), control and MAFF ($p = .868$), or MAFF and $A\beta + MAFF$ ($p = .994$). Similar results were observed with $A\beta_{1-42}$.

Figure 10 shows the effect of Ca^{2+} -independent PLA_2 (type VI) inhibition on $A\beta$ -induced vasoactivity. Certain aortic rings were treated with $1 \mu M$ of freshly solubilized $A\beta_{1-40}$, $1 \mu M$ of HELSS, $HELSS + A\beta$, or untreated (control) 5 minutes prior to the addition of a dose range of ET-1. There were significant main effects by ANOVA of ET-1 dose ($p < .001$), $A\beta$ ($p < .001$), but not for HELSS ($p = .01$). There was also a significant interactive term between ET-1 dose and $A\beta$ ($p < .001$), but not among ET-1, $A\beta$ and HELSS ($p = .661$).

Contribution of arachidonic acid metabolism to A β vasoactivity

The data thus far had shown that A β mediates its vasoactive effect by activating specific PLA₂ isoforms. Activation of cPLA₂ results in the production of AA, since cPLA₂ displays strict substrate specificity for AA-containing phospholipids. AA is metabolized essentially through two distinct pathways, the COX pathway, which leads to the production of prostaglandins and thromboxanes, and the LOX pathway, which gives rise to leukotrienes and lipoxins. The effect of NS-398, a specific inhibitor of COX-2, on the vasoactivity mediated by A β was investigated first. It was observed that NS-398 is able to block A β vasoactivity in a statistically interactive manner, showing that A β enhancement of vasoconstriction is mediated through COX-2 (Figure 11). The effect of MK-886, a compound which impairs the translocation of 5-LOX and its subsequent activation by 5-LOX activating protein, was then tested which showed that MK-886 also markedly inhibits A β vasoactivity in a statistically interactive manner, showing that A β -vasoactivity is mediated via the 5-LOX pathway. (Figure 12).

AA can also be produced via diacylglycerol (DAG, a product of PLC) hydrolysis by DAG-lipase. A specific inhibitor of DAG-lipase, RHC-80267, was used and this showed that DAG-lipase does not contribute to A β vasoactivity, since RHC-80267 is not able to modulate ET-1-induced vasoconstriction or to affect A β enhancement of ET-1-induced vasoconstriction (Figure 13). However, treatment of vessels with DAG was able to potentiate ET-1-induced vasoconstriction, as well as A β enhancement of vasoconstriction, but this effect was merely additive

(Figure 14), suggesting that DAG does not impinge upon the A β pathway leading to vasoactivity. Since DAG is an endogenous stimulator of PKC, the data suggests that A β vasoactivity is PKC independent. To further substantiate this hypothesis, PKC was specifically inhibited by using bisindolylmaleimide I, and there was observed a statistically interactive reduction in ET-1-induced vasoconstriction, while reduction in A β vasoactivity was merely additive (Figure 15). Taken together, these data demonstrate that A β vasoactivity is not mediated through PLC or PKC-associated pathways, and that stimulation of the PLA $_2$ pathway by A β is responsible for AA production which mediates A β vasoactivity.

Specifically, Figure 11 shows the effect of COX-2 inhibition on A β -enhancement of ET-1-induced vasoconstriction. Certain aortic rings were treated with 1 μ M of freshly solubilized A β_{1-40} , 5 μ M of NS-398, NS-398 + A β , or untreated (control) 5 minutes prior to the addition of a dose-range of ET-1. ANOVA revealed significant main effects of ET-1 dose ($p < .001$), A β ($p < .001$), and of NS-398 ($p < .001$). There were also significant interactive terms between ET-1 dose and either A β ($p < .001$) or NS-398 ($p < .001$), and among ET-1 dose, A β and NS-398 ($p < .001$). One-way ANOVA across ET-1 doses revealed significant between-groups differences ($p < .001$), and post-hoc testing showed significant differences between control and A β ($p < .001$), and A β and A β + NS-398 ($p = .001$), but not between control and A β + NS-398 ($p = .393$), control and NS-398 ($p = .996$), or NS-398 and A β + NS-398 ($p = .249$). Similar results were observed with A β_{1-42} .

Further, Figure 12 shows the interaction among MK-886, $\text{A}\beta_{1-40}$, and ET-1 on vasoconstriction. Certain aortic rings were treated with 1 μM of freshly solubilized $\text{A}\beta_{1-40}$, 1 μM of MK-886, MK-886 + $\text{A}\beta$, or untreated (control) 5 minutes prior to the addition of a dose range of ET-1. There were significant main effects by ANOVA of ET-1 dose ($p < .001$), $\text{A}\beta$ ($p < .001$), and MK-886 ($p < .05$). There was also a significant interaction between ET-1 dose and $\text{A}\beta$ ($p < .001$), and among ET-1 dose, $\text{A}\beta$, and MK-886 ($p = .001$). However, an interaction between ET-1 dose and MK-886 ($p = .159$) was noted. One-way ANOVA across the 2.5 and 5 nM doses of ET-1 revealed significant between-groups differences ($p < .001$), and post-hoc testing showed significant differences between control and $\text{A}\beta$ ($p < .001$), $\text{A}\beta$ and $\text{A}\beta$ + MK-886 ($p < .01$), and control and $\text{A}\beta$ + MK-886 ($p < .05$), but not between control and MK-886 ($p = .639$), or MK-886 and $\text{A}\beta$ + MK-886 ($p = .286$). Similar results were observed with $\text{A}\beta_{1-42}$.

Figure 13 shows the effect of RHC-80267 on $\text{A}\beta$ -enhancement of ET-1-induced vasoconstriction. Certain aortic rings were treated with 1 μM of freshly solubilized $\text{A}\beta_{1-40}$, 8 μM of RHC-80267, RHC-80267 + $\text{A}\beta$, or untreated (control) 5 minutes prior to the addition of a dose range of ET-1. ANOVA revealed significant main effects of ET-1 dose ($p < .001$), $\text{A}\beta$ ($p < .001$), and RHC-80267 ($p = .001$). There was also a significant interactive term between ET-1 dose and $\text{A}\beta$ ($p < .001$), but not between ET-1 dose and RHC-80267 ($p = .222$) or among ET-1 dose, $\text{A}\beta$ and RHC-80267 ($p = .482$).

Figure 14 shows the effect of DAG on $A\beta$ -enhancement of ET-1-induced vasoconstriction. Certain aortic rings were treated with 1 μ M of freshly solubilized $A\beta_{1-40}$, 10 μ M of diacylglycerol (DAG), DAG + $A\beta$, or untreated (control) 5 minutes prior to the addition of a dose range of ET-1. ANOVA revealed significant main effects of ET-1 dose ($p < .001$) and $A\beta$ ($p < .001$), but not DAG ($p = .248$). There was also a significant interactive term between ET-1 dose and $A\beta$ ($p < .05$), but not between ET-1 dose and DAG ($p = .397$) and not among ET-1 dose, $A\beta$ and DAG ($p = .123$).

Figure 15 shows the effect of bisindolylmaleimide I on $A\beta$ -enhancement of ET-1-induced vasoconstriction. Certain aortic rings were treated with 1 μ M of freshly solubilized $A\beta_{1-40}$, 1.5 μ M of bisindolylmaleimide I (bisindol.), bisindol. + $A\beta$, or untreated (control) 5 minutes prior to the addition of a dose range of ET-1. ANOVA revealed significant main effects of ET-1 dose ($p < .001$), $A\beta$ ($p < .001$), but not of bisindol. ($p > .05$). There were also significant interactive terms between ET-1 dose and either $A\beta$ ($p < .001$) or bisindol. ($p < .001$), but not among ET-1 dose, $A\beta$ and bisindol. ($p = .184$).

Cross-talk between sPLA₂ and cPLA₂

Both sPLA₂ and cPLA₂ appeared to be necessary to mediate $A\beta$ -vasoactivity from the data presented thus far, leaving the possibility open that cross-talk between these PLA₂s could be implicated in $A\beta$'s vasoactivity. A complex network of interactions exists among the various PLA₂ isoforms. In particular, a functional cross-talk between type I sPLA₂ and cPLA₂, which is mediated by the MAPK

module, has recently been demonstrated (Hernandez et al., 1998; Huwiler et al., 1997; Naidu et al., 1995). Thus, potential MAPK module-mediated cross-talk between these PLA₂s was investigated in the vessel bath system. Vessels were pre-treated with PD 98059, a highly specific MEK1/2 (MAPK kinase) inhibitor that has been shown to completely block sPLA₂-induced cPLA₂ activation (Huwiler et al., 1997). A complete blockade of A β ₁₋₄₀ and A β ₁₋₄₂ vasoactivity by PD 98059 was observed, showing that MEK1/2 activity is necessary to mediate A β vasoactivity (Figures 16 and 17). Interestingly, PD 98059 was also able to completely inhibit sPLA₂ enhancement of ET-1-induced vasoconstriction, showing that sPLA₂'s induction of vasoconstriction, like A β 's, is essentially mediated via MEK1/2 (Figure 18). Moreover, pretreatment of vessels with a specific inhibitor of p38 MAPK, SB 202190, resulted in complete inhibition of A β vasoactivity, further substantiating the involvement of the MAPK module in A β signaling (Figure 19).

Figure 16 shows the effect of MEK1/2 inhibition on A β ₁₋₄₀-enhancement of ET-1-induced vasoconstriction. Certain aortic rings were treated with 1 μ M of freshly solubilized A β ₁₋₄₀, 25 μ M of PD98059, PD98059 + A β , or untreated (control) 5 minutes prior to the addition of a dose range of ET-1. ANOVA revealed significant main effects of ET-1 dose ($p < .001$), A β ($p < .001$), and of PD98059 ($p < .001$). There were also significant interactive terms between ET-1 dose and either A β ($p < .001$) or PD98059 ($p < .001$), and among ET-1 dose, A β and PD98059 ($p < .001$). One-way ANOVA across ET-1 doses revealed significant between-groups differences ($p < .001$), and post-hoc testing showed significant differences between control and A β ($p < .001$),

0152.00343

A β and A β + PD98059 ($p < .001$) and control and A β + PD98059 ($p < .001$), but not between control and PD98059 ($p = 1.00$), or PD98059 and A β + PD98059 ($p = .880$).

Figure 17 shows the effect of MEK1/2 inhibition on A β_{1-42} -enhancement of ET-1-induced vasoconstriction. Certain aortic rings were treated with 1 μ M of freshly solubilized A β_{1-42} , 25 μ M of PD98059, PD98059 + A β , or untreated (control) 5 minutes prior to the addition of a dose range of ET-1. ANOVA revealed significant main effects of ET-1 dose ($p < .001$), A β ($p < .001$), and of PD98059 ($p < .001$). There were also significant interactive terms between ET-1 dose and either A β ($p < .001$) or PD98059 ($p < .001$), and among ET-1 dose, A β and PD98059 ($p < .001$). One-way ANOVA across ET-1 doses revealed significant between-groups differences ($p < .001$), and post-hoc testing showed significant differences between control and A β ($p < .001$), A β and A β + PD98059 ($p < .001$) and control and A β + PD98059 ($p < .001$), but not between control and PD98059 ($p = 1.00$), or PD98059 and A β + PD98059 ($p = .780$).

Figure 18 shows the effect of MEK1/2 inhibition on sPLA $_2$ -enhancement of ET-1-induced vasoconstriction. Certain aortic rings were treated with 2.5 U/mL of sPLA $_2$, 25 μ M of PD98059, PD98059 + sPLA $_2$, or untreated (control) 5 minutes prior to the addition of a dose range of ET-1. ANOVA revealed significant main effects of ET-1 dose ($p < .001$), PD98059 ($p < .001$), and of sPLA $_2$ ($p < .001$). There were also significant interactive terms between ET-1 dose and either sPLA $_2$ ($p < .001$) or PD98059 ($p = .01$), and among ET-1 dose, sPLA $_2$ and PD98059 ($p < .05$). One-way ANOVA across

ET-1 doses revealed significant between-groups differences ($p < .001$), and post-hoc testing showed significant differences between control and $sPLA_2$ ($p < .001$), $sPLA_2$ and $sPLA_2 + PD98059$ ($p < .001$), control and $sPLA_2 + PD98059$ ($p < .05$) and $PD98059$ and $sPLA_2 + PD98059$ ($p < .01$), but not between control and $PD98059$ ($p = 1.00$).

Additionally, Figure 19 shows the effect of p38 MAPK inhibition on $A\beta$ -enhancement of ET-1-induced vasoconstriction. Certain aortic rings were treated with $1 \mu M$ of freshly solubilized $A\beta_{1-40}$, $5 \mu M$ of SB202190, SB202190 + $A\beta$, or untreated (control) 5 minutes prior to the addition of a dose range of ET-1. ANOVA revealed significant main effects of ET-1 dose ($p < .001$), $A\beta$ ($p < .001$), and of SB202190 ($p < .001$). There were also significant interactive terms between ET-1 dose and either $A\beta$ ($p < .001$) or SB202190 ($p < .001$), and among ET-1 dose, $A\beta$ and SB202190 ($p < .001$). One-way ANOVA across ET-1 doses revealed significant between-groups differences ($p < .001$), and post-hoc testing showed significant differences between control and $A\beta$ ($p < .001$) and $A\beta$ and $A\beta + SB202190$ ($p < .001$), but not between control and $A\beta + SB202190$ ($p = .858$), SB202190 and $A\beta + SB202190$ ($p = .519$), or control and SB202190 ($p = .885$). Similar results were observed with $A\beta_{1-42}$.

Modulation of [3H] AA release by $A\beta$ in rat aortae

Since the data suggested that $A\beta$ vasoactivity was mediated by activation of PLA_2 , the ability to stimulate the release of AA from intact aortic rings was investigated. As previously described, activation of PLA_2 can be detected by pre-incubating cells or intact rat aortae with [3H]AA and

measuring [^3H]AA release (Naidu et al., 1995). Figure 20 shows that treatment of aortic rings with sPLA₂ results in an increased release of [^3H]AA, confirming the validity of such an experiment to detect elevated [^3H]AA release in response to increased PLA₂ activity. It has been observed that A β enhances the release of [^3H]AA from aortic rings in comparison to controls rings, further substantiating that A β stimulates PLA₂ activity (Figure 21). Moreover, this increase in [^3H]AA induced by A β is inhibited by co-treating vessels with AACOCF₃, a specific cPLA₂ inhibitor, showing that cPLA₂ mediates the release of AA induced by A β (see Figure 21). A β -induced [^3H]AA release is also blocked by PD98059 (Figure 22), confirming the requirement of MEK1/2 activity for A β -induced stimulation of cPLA₂. Taken together, these data further demonstrate that A β induces activation of cPLA₂ via stimulation of MEK1/2.

Figure 20 shows the effect of sPLA₂ on [^3H]AA release. Intact aortic rings were incubated with [^3H]AA in PSS for 24 hours at 4°C. Unincorporated [^3H]AA was removed by multiple washes in Kreb's buffer, and then aortic rings were preincubated in the vessel bath system for 5 minutes with 10 U/mL of sPLA₂ or untreated (control) prior to treatment with a dose range of ET-1. ANOVA revealed significant main effects of ET-1 dose ($p < .001$) and sPLA₂ ($p < .001$). Post-hoc t-test for independent samples revealed a significant difference ($p < .001$) between control and A β -treated vessels across the 1 nM to 5 nM ET-1 dose range.

Specifically, Figure 21 shows the effect of cPLA₂ inhibition on [^3H]AA release induced by A β . Intact aortic

rings were incubated with [3 H]AA in PSS for 24 hours at 4°C. Unincorporated [3 H]AA was removed by multiple washes in Kreb's buffer, and then aortic rings were preincubated in the vessel bath system for 5 minutes with $A\beta_{1-40}$ (1 μ M), AACOCF3 (1 μ M), $A\beta_{1-40}$ + AACOCF3, or untreated (control) prior to treatment with a dose range of ET-1. ANOVA revealed significant main effects of ET-1 dose ($p < .001$), $A\beta$ ($p < .001$), and AACOCF3 ($p < .001$). One-way ANOVA including the 1nM to 5 nM ET-1 doses showed significant between-groups differences ($p < .001$), and post-hoc testing showed significant differences between control and $A\beta$ ($p < .01$), control and AACOCF3 ($p < .001$), and between $A\beta$ and AACOCF3 + $A\beta$ ($p < .001$).

Figure 22 shows the effect of MEK1/2 inhibition on [3 H]AA release induced by $A\beta$. Intact aortic rings were incubated with [3 H]AA in PSS for 24 hours at 4°C. Unincorporated [3 H]AA was removed by multiple washes in Kreb's buffer, and then aortic rings were preincubated in the vessel bath system for 5 minutes with $A\beta_{1-40}$ (1 μ M), PD98059 (25 μ M), $A\beta_{1-40}$ + PD98059, or untreated (control) prior to treatment with a dose range of ET-1. ANOVA revealed significant main effects of ET-1 dose ($p < .001$), $A\beta$ ($p < .001$), and PD98059 ($p < .001$). One-way ANOVA including the 1nM to 5 nM ET-1 doses showed significant between-groups differences ($p < .001$), and post-hoc testing showed significant differences between control and $A\beta$ ($p < .01$), control and PD98059 ($p < .01$), and between $A\beta$ and PD98059 + $A\beta$ ($p < .01$).

Discussion

Vascular pathology is the norm in advanced cases of AD, with cerebral amyloid angiopathy (CAA) being one of the commonest abnormalities detected at autopsy in carefully standardized examination (83% of AD cases as assessed by CERAD; 12). It has been shown that soluble A β peptides display vasoactive properties; specifically, they are able to enhance the magnitude of contraction induced by ET-1 (Crawford et al., 1998; Paris et al., 1998), and to oppose the relaxation induced by acetylcholine (Tischfield, J.A., 1997) or nitric oxide (Rogers et al., 1993). In addition, rats intra-arterially infused with freshly solubilized A β exhibit decreased cerebral blood flow (Thomas et al., 1996), and transgenic mice which overproduce A β peptides display enhanced cerebrovascular constriction and resistance to relaxation in response to exogenous application of vasoconstrictors and vasorelaxants, respectively (Iadecola et al., 1999).

These data suggest that, in life, elevated levels of circulating A β may have similar effects on the peripheral and cerebral vasculature. At the clinical level, the possibility arises that this effect of soluble A β contributes to hypoperfusion and perhaps ischaemia in AD brains, thereby amplifying the AD pathological process. With regard to hypoperfusion, both SPECT and PET studies confirm reduction in cerebral blood flow in AD (Duara et al., 1986; Johnson et al., 1987). As a first step to elucidating the contribution of A β to the vascular pathology associated with AD, the focus was placed on determining how A β mediates its vasoactive effects.

Several converging lines of evidence suggest that

A β peptides and inflammation may be linked in the pathogenesis of AD. For example, senile plaques observed in AD are sites of classical inflammatory processes, as evidenced by the presence of numerous degenerating neurons, reactive microglia and astrocytes, cytokines, and complement proteins (Itagaki et al., 1989; Minami et al., 1993; Wisniewski et al., 1993). In addition, cPLA₂ immunoreactivity has been shown to be increased in AD brains, specifically in reactive astrocytes in regions that contain numerous A β deposits (Stewart et al., 1997), suggesting a potential association between cPLA₂ and AD pathology. Furthermore, reactive glia are frequently co-localized with cerebral microvessels in AD brains (Wisniewski et al., 1992; Zhu et al., 1998), suggesting that the vasculature may be a site of inflammatory processes. Based on such evidence, the possible relationship between the vasoactive properties of A β and inflammation was investigated.

A β vasoactivity is mediated by a pro-inflammatory pathway, the PLA₂ cascade, which plays a role in signal transduction by allowing the production of bioactive lipids (Dennis et al., 1991; Sisoda et al., 1995). The results show that the vasoactive properties of A β are specifically mediated by type I sPLA₂ and cPLA₂, but not by type II sPLA₂ or type VI calcium-independent PLA₂. Type I sPLA₂ is abundant in pancreatic juice in many mammals, and thus is frequently referred to as pancreatic sPLA₂, and was originally thought to be involved in digestion of glycerophospholipids in nutrients. However, increased levels of type I sPLA₂ mRNA and protein are produced by non-digestive cells, where it may act as a regulator of cellular functions via the sPLA₂ receptor (sPLA₂-R), or via

the direct release of bioactive fatty acids (Lehtonen et al., 1996; Itagaki et al., 1989; Tsunoda et al., 1995).

The data show that inhibition of either type I sPLA₂ or cPLA₂ is sufficient to block A β vasoactivity, suggesting that these two enzymes act in concert to bring about A β vasoactivity. This idea is supported by the existence of a sophisticated network of interactions (cross-talk) between various PLA₂s. Interestingly, it has been shown that the products of sPLA₂'s catalytic action, specifically lysophosphatidylcholine, lysophosphatidic acid and *cis*-unsaturated fatty acids (including arachidonic acid), activate PKC and the classical MAPK module (including Raf-1 kinase, MEK and the p44/42 and p38 isoforms of MAPK).

Ultimately, sPLA₂'s catalytic action has been shown to phosphorylate and activate cPLA₂ via PKC, p42/p44 or p38 MAPK in various cell systems (Hernandez et al., 1998; Husain et al., 1998; Huwiler et al., 1997; Kan et al., 1996). In order to determine which kinases were responsible for sPLA₂-cPLA₂ cross-talk in the system, the effect of PKC modulation was first evaluated. Both DAG, an endogenous stimulator of PKC, and bisindolylmaleimide I, a specific inhibitor of PKC, were able to enhance and reduce A β vasoactivity, respectively. Yet, these effects were merely additive (no interaction was noted by ANOVA), showing that PKC does not provide for sPLA₂-cPLA₂ cross-talk to ensure A β vasoactivity. Since metabolism of DAG by DAG-lipase leads to AA production independently of the PLA₂ system, the effect of a specific inhibitor of DAG-lipase, RHC-80267, was assessed and it was found that this compound fails to block A β vasoactivity, showing that neither DAG-lipase nor

the DAG-derived AA mediates A β vasoactivity. Because DAG is a product of phospholipase C (PLC), these data also suggest that A β vasoactivity is PLC-independent. Moreover, propranolol, which has been shown to inhibit PLD, is unable to block A β vasoactivity.

In order to determine if the cross-talk between type I sPLA $_2$ and type IV cPLA $_2$ was mediated by the MAPK module in the system, rat aortae were pre-incubated with PD 98059 or SB 202190, which block the activity of MEK1/2 (resulting in blockade of downstream p42/p44 MAPK, Dudley et al., 1995) or p38 MAPK, respectively. PD 98059 and SB 202190 have also been shown to inhibit the phosphorylation and activation of type IV cPLA $_2$ (Borsch-Haubold et al., 1998; Hernandez et al., 1998; Husain et al., 1998; Huwiler et al., 1997). PD 98059 completely abolished A β vasoactivity as well as A β -induced [3 H]AA release, showing that MEK1/2 activation is required to insure functional sPLA $_2$ -cPLA $_2$ cross-talk which mediates A β vasoactivity. SB 202190 addition also resulted in blockade of A β vasoactivity, supporting the requirement of p38 MAPK in promotion of this effect. Since stimulation of the MAPK module results in cPLA $_2$ activation, the contribution of cPLA $_2$ to A β 's bioactivity was assessed. Cytosolic PLA $_2$ inhibition (by MAFP or AACOCF3) also blocked both A β vasoactivity and A β -induced [3 H]AA release from rat aortae.

Several studies have demonstrated that a variety of biological responses induced by type I sPLA $_2$ are mediated via sPLA $_2$ -R, including cell proliferation (Arita et al., 1991), progression of endotoxic shock (Hanasaki et al., 1997), cell invasion (Kundu et al., 1997), chemokinesis (Kanemasa et al., 1992), eicosanoid production (Kishino et

al., 1994; Tohkin et al., 1993), airway and vascular smooth muscle contraction (Kanemasa et al., 1992; Nitsch et al., 1992), and fertilization (Okamoto et al., 1995).

The sPLA₂-R has sequence homologies to the macrophage mannose receptor, a membrane protein involved in the endocytosis of glycoproteins. The short cytoplasmic tail of the sPLA₂-R does not display any characteristic sequence motif that could be responsible for coupling to known signaling pathways. However, it has been suggested that sPLA₂, independently of its catalytic action, can activate cPLA₂ on a human astrocytoma cell line via a mechanism involving sPLA₂-R, since an antagonist of this receptor, p-aminophenyl- α -D-mannopyranoside-bovine serum albumin (mannose-BSA) blocks cPLA₂ activation induced by sPLA₂ (Hernandez et al., 1998). The effect of sPLA₂-R blockade was investigated using mannose-BSA. A statistical interaction among mannose-BSA, A β and ET-1 was noted but does not allow the conclusion that a stimulation of the sPLA₂-R may contribute to A β vasoactivity, since mannose-BSA was vasoactive to a similar extent as A β in the assay. Moreover, inactivation of sPLA₂ with dithiothreitol or oleyloxyphosphocholine, which does not block the binding of sPLA₂ to its receptor, results in the inhibition of sPLA₂-induced vasoconstriction, showing that the sPLA₂-R is not required for sPLA₂-induced vasoactivity. These data further suggest that the cross-talk between sPLA₂ and cPLA₂, which results in A β vasoactivity, is not significantly affected by the sPLA₂-R, but is promoted by a product of sPLA₂.

Since cPLA₂ displays a strict substrate specificity for AA-containing phospholipids, the A β -induced cPLA₂ signaling pathway will result in an increase in

production of AA, and thus a possible enhancement of eicosanoids via COXs and LOXs. It was observed that AA can enhance ET-1-induced constriction and also noted a statistical interaction among A β , AA and ET-1, showing that AA mediates A β vasoactivity. It was also shown that A β results in an increased release of [3 H]AA in the system, providing for two possibilities; either AA is directly effecting A β vasoactivity, or downstream eicosanoid products of AA are responsible. NS-398, a specific inhibitor of COX-2 (Futaki et al., 1994), was able to block A β vasoactivity. Moreover, MK-886, a specific inhibitor of the 5-LOX activating protein (which allows for translocation of 5-LOX to the membrane and its subsequent activation; Abramovitz et al., 1993), was also able to block A β vasoactivity, demonstrating the requirement of 5-LOX for A β signaling. Interestingly, simultaneous COX-2 and 5-LOX inhibition resulted in the complete blockade of A β vasoactivity, confirming that both COX-2 and 5-LOX cooperatively mediate A β vasoactivity.

Therefore, the initiating event leading to A β vasoactivity is a stimulation of type I sPLA $_2$ activity followed by activation of p44/42 and p38 MAPKs, which will induce cPLA $_2$ phosphorylation, leading to its activation and ultimately to the production of AA. Finally, downstream of AA production, 5-LOX and COX-2 can mediate A β vasoactivity via multiple eicosanoid endproducts. A β can induce the release of leukotriene B $_4$, a stable eicosanoid product of 5-LOX, from microglia, showing that A β stimulates a common signal transduction pathway in different cell types (Rogers et al., 1993). In cell-free experiments, A β peptides have been shown to induce type I sPLA $_2$ activity (Lin et al.,

1993). Furthermore, there is considerable evidence for an abnormal phospholipid metabolism in AD patients, as mentioned previously. Such evidence points principally to increased degradation of membrane phospholipids in AD brains, where marked increases have been reported in the levels of prostaglandins and lipid peroxides (Iwamoto et al., 1989), both products of PLA₂ activity.

Taken together, the data show that A β vasoactivity is mediated by a pro-inflammatory response, showing a link between AD-type vascular pathology and inflammation. Although it is generally regarded that aggregated and fibrillar A β deposits in amyloid plaques can trigger inflammation, soluble forms of the peptide have not been previously investigated in relation to inflammation.

EXAMPLE 2

The following example serves to illustrate that the sPLA₂/AA/5-LOX/COX-2 pathway is also activated by soluble A β peptides in microglia, providing for an additional system where A β peptides stimulate this pathway. Additionally, this example illustrates that substances which inhibit this pathway block the effect of A β in microglia.

Methods

Leukotriene B₄ (LTB₄) enzyme-linked immunoabsorbant assay (ELISA). Quantitative determination of LTB₄ levels was made using a competitive binding ELISA (R&D Systems, Minneapolis, MN) designed to measure LTB₄ in cell culture supernatants (as described in Paris et al., Exp Neurol 1999). A murine microglial cell line (N9) was

provided by Dr. Paola Ricciardi-Castagnoli (Cellular Pharmacology Center, Milan, Italy) and were grown in RPMI medium supplemented with five percent fetal calf serum, 2mM glutamine, 100 U/mL penicillin, 0.1 µg/mL streptomycin and 0.05 mM 2-mercaptoethanol. Microglial cells were seeded at 50,000 cells/well in 6-well plates (Falcon, France) and treated with AB_{1-40} (500 nM), drugs which oppose the PLA2/AA/5-LOX/COX-2 pathway, or untreated (control) and incubated for 18 hours. Cell supernatants were then collected and diluted 10-fold in assay buffer. 50 µL of diluted samples were then used in the assay, and each sample was assayed in duplicate. Manipulations were performed in accordance with the manufacturer's instruction. A spectramax 250 spectrophotometer (Molecular Devices, San Diego, USA) was used to measure absorbance at 405 nm and a standard curve was plotted using a 4-parameter model.

Measurement of [3 H]AA release in cultured cells.

Microglial cells were cultured as described above, seeded at 50,000 cells/well in 6-well plates (Falcon, France), and incubated with 0.4 µCi/mL [3 H]AA for 18 h. Cells were washed multiple times with 1 mL of complete medium and were then treated with 1 µM of AB_{1-40} or 10 U/mL of sPLA2 for 5 h. Cell culture supernatants were collected each hour following treatment and radioactivity was quantified as described above.

Statistical analysis. Analysis of variance

(ANOVA) was used to analyze the data, with post-hoc comparisons of means carried out where appropriate by Sheffe's or Bonferonni's methods. As previously described (Paris et al., Neurosci Lett, 1998), a significant interactive term by ANOVA was taken as evidence that both

drug x and A β are modulating a common signal transduction pathway. However, if the effect of drug x and A β was simply additive (or subtractive), this suggested modulation of independent transduction pathways. Levene's test for equality of variance followed by t-test for independent samples was used for single mean comparisons. Alpha levels were set at 0.05 for all analyses. Analyses were performed using SPSS for Windows release 9.5.

Results and Discussion

Effect of A β on microglial LTB₄ release. As shown in Figure 23, soluble A β_{1-40} treatment of the murine microglial cell line, N9, results in an increased release of LTB₄. Also shown in this figure is that COX-2 inhibition (via the COX-2 specific inhibitor, NS-398, 50 μ M) results in complete blockade of LTB₄ release. Furthermore, inhibition of p38 MAPK by the specific inhibitor SB202190 (5 μ M) or inhibition of MEK1/2 via PD98059 (25 μ M) each result in complete blockade of A β -induced microglial LTB₄ release.

Figure 23 shows that A β -induced microglial LTB₄ release is blocked by inhibiting elements of the sPLA₂/AA/5-LOX/COX-2 pathway. N9 microglial cells were treated as described in materials and methods. N = 6 for control, n = 5 for A β , n = 5 for NS-398 + A β , n = 4 for SB202190 + A β , and n = 6 for PD98059 + A β . ANOVA revealed significant treatment interactions between A β and drug x (p < .001). One-way ANOVA revealed a significant difference between the A β treatment condition and control (p < .001),

but no significant differences were noted between drug x + A β and control ($p > .05$), indicating complete blockade of A β -induced LTB₄ release by inhibitors of elements of the PLA₂/AA/5-LOX/COX-2 pathway.

Effect of A β on microglial [³H]AA release.

In order to determine if A β could stimulate PLA₂ activity, resulting in increased release of AA, N9 microglia was incubated with [³H]AA and then treated with sPLA₂ or soluble A β ₁₋₄₀. As shown in Figure 24, secretory PLA₂ induces the release of [³H]AA, confirming the validity of such an assay to measure increased PLA₂ activity. Most importantly, soluble A β ₁₋₄₀ also stimulates AA release from N9 microglia, confirming that soluble A β activates the PLA₂/AA/5-LOX/COX-2 pathway in microglia.

Additionally, Figure 24 shows that sPLA₂ and A β induce [³H]AA release in N9 microglia. N9 microglia were treated as described in materials and methods. N = 6 for each condition presented. ANOVA revealed significant main effects of A β treatment ($p < .001$), sPLA₂ treatment ($p < .001$), and time ($p < .001$). There were also significant interactive terms between time and either A β or sPLA₂ treatment ($p < .001$). T-test for independent samples showed significant differences in the means across time points between sPLA₂ treatment and control ($p < .001$), and between A β treatment and control ($p < .001$).

EXAMPLE 3

This example illustrates the effect of soluble A β on a neuronal model (NGF- β differentiated PC12 cells). The

data presented here, like those in example 2, demonstrate that soluble A β peptides stimulate the sPLA2/AA/5-LOX/COX-2 pathway. In this example it is further highlighted that soluble A β peptides are able to trigger the pathway in various cell types.

Methods

Measurement of [³H]AA release in neuronal cells (cultured differentiated PC12 cells). A rat pheochromocytoma cell line (PC12) was grown in Kahn's modification of F12 medium supplemented with 10% fetal calf serum, 100 U/mL penicillin and 0.1 μ g/mL streptomycin. PC12 cells were seeded at 35,000 cells/well and differentiated with 60 ng/mL NGF- β for 5-6 days and then maintained with 5 ng/mL NGF- β thereafter. PC12 cells were treated with 0.4 μ Ci/mL of [³H]AA for 18 h and were washed multiple times with 1 mL of complete medium to remove unincorporated [³H]AA. Cells were then treated with 1 μ M of A β_{1-40} or 40 U/mL of sPLA2 for 5 h. Cell culture supernatants were collected each hour following treatment and radioactivity was quantified as described above.

Immunolocalization of activated p38 MAPK in neuronal cells. Cells were treated as described above, and were plated on glass cover-slips which had been soaked in 10 μ g/mL of mouse laminin. Following differentiation, neuronal cells were treated with soluble A β_{1-40} (5 μ M) or anasomycin (20 μ M, a known stimulator of p38 MAPK) for 10 and 20 min, and immediately fixed in 4% paraformaldehyde in 0.1 M PBS, pH 7.4 for 30 min at 4°C. Cells were washed multiple times in PBS, and incubated for 3 h with a

phospho-specific antibody recognizing active active p38 MAPK. Cells were then washed multiple times in PBS and incubated with a secondary HRP-conjugated antibody. Immunostaining was performed using the DAKO ABC kit, cells were counterstained with hematoxylin-eosin, and cells were then observed under a microscope.

Statistical analysis. Analysis of variance (ANOVA) was used to analyze the data, with post-hoc comparisons of means carried out where appropriate by Sheffe's or Bonferonni's methods. Levene's test for equality of variance followed by t-test for independent samples was used for single mean comparisons. Alpha levels were set at 0.05 for all analyses. Analyses were performed using SPSS for Windows release 9.5.

Results and Discussion

Soluble A β peptides induce [3 H]AA release in neuronal cells. Cultured differentiated PC12 cells were treated as described above, and, in order to determine if A β could stimulate PLA2 activity resulting in increased release of AA, cultured differentiated PC12 cells were incubated with [3 H]AA and then treated with sPLA2 or soluble A β_{1-40} . As shown in Figure 25, secretory PLA2 induces the release of [3 H]AA, confirming the validity of such an assay to measure increased PLA2 activity. Most importantly, soluble A β_{1-40} also stimulates AA release from neuronal cells, confirming that soluble A β activates the PLA2/AA/5-LOX/COX-2 pathway in these cells.

Figure 25 shows the soluble A β peptides induce [3 H]AA release in neuronal cells. Cultured differentiated PC12 cells were treated as described in materials and methods. N = 3 for each group presented. ANOVA revealed significant main effects of treatment with soluble A β peptides (p < .001) and sPLA2 treatment (p < .001). One-way ANOVA followed by post-hoc comparison revealed significant differences from 3 h onward between control and either sPLA2 treatment (p = .001) or treatment with soluble A β peptides (p < .01).

Soluble A β peptides activate p38 MAPK in neuronal cells. As shown in Figure 26, soluble A β increases the phosphorylation of p38 MAPK, and induces the translocation from the cytosol to the nucleus in neuronal cells. Thus, soluble A β mimics the effect of anisomycin, a known stimulator of p38 MAPK, indicating that soluble A β activates p38 MAPK, an element of the PLA2/AA/5-LOX/COX-2 pathway.

Additionally, Figure 26 shows the activation of p38 MAPK by soluble A β peptides in neuronal cells. Cultured differentiated PC12 cells were treated as described in materials and methods. Micrographs are at 40X magnification in bright-field. Brown staining reveals the intracellular location of activated p38 MAPK, and blue staining reveals the nucleus. In untreated (control) cells, little brown immunostaining is evident, and located essentially in the cytosol. In cells treated with either anisomycin or soluble A β peptides, brown immunostaining is intensified, and a strong nuclear staining is evident, showing that p38 MAPK is activated.

Throughout this application, various publications, including United States patents, are referenced by author and year and patents by number. Full citations for the publications are listed below. The disclosures of these publications and patents in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art to which this invention pertains.

The invention has been described in an illustrative manner, and it is to be understood that the terminology which has been used is intended to be in the nature of words of description rather than of limitation.

Obviously, many modifications and variations of the present invention are possible in light of the above teachings. It is, therefore, to be understood that within the scope of the appended claims, the invention may be practiced otherwise than as specifically described.

REFERENCES

- Abramovitz, M., E. Wong, M.E. Cox, C.D. Richardson, C. Li, and P.J. Vickers. 5-lipoxygenase-activating protein stimulates the utilization of arachidonic acid by 5-lipoxygenase. *Eur. J. Biochem.* 215:105-11, 1993.
- Arita, H., K. Hanasaki, T. Nakano, S. Oka, H. Teraoka, and K. Matsumoto. Novel proliferative effect of phospholipase A2 in Swiss 3T3 cells via specific binding site. *J. Biol. Chem.* 266:19139-41, 1991.
- Basso, D., C. Fabris, M.P. Panozzo, T. Meggiato, G. Del Favero, and R. Naccarato. Serum phospholipase A2 activity in chronic pancreatic diseases. *Clin. Biochem.* 23:229-32, 1990.
- Borsch-Haubold, A.G., S. Pasquet, and S.P. Watson. Direct inhibition of cyclooxygenase-1 and -2 by the kinase inhibitors SB 203580 and PD 98059. SB 203580 also inhibits thromboxane synthase. *J. Biol. Chem.* 273:28766-72, 1998.
- Clark, J.D., L.L. Lin, R.W. Kriz, C.S. Ramesha, L.A. Sultzman, A.Y. Lin, N. Milona, and J.L. Knopf. A novel arachidonic acid-selective cytosolic PLA2 contains a Ca(2+)-dependent translocation domain with homology to PKC and GAP. *Cell* 65:1043-1051, 1991.
- Coria, F., A. Moreno, I. Rubio, M.A. Garcia, E. Morato, and F. Mayor. The cellular pathology associated with Alzheimer b-amyloid deposits in non-demented aged individuals. *Neuropathol. Appl. Neurobiol.* 19:261-268, 1993.
- Crawford, F., Z. Suo, C. Fang, and M. Mullan. Characteristics of the in Vitro Vasoactivity of beta-amyloid peptides. *Exp. Neurol.* 150:159-168, 1998.
- Dennis, E.A., S.G. Rhee, M.M. Billah, and Y.A. Hannun. Role of phospholipase in generating lipid second messengers in signal transduction. *FASEB J.* 5:2068-77, 1991.
- Dennis, E.A. The growing phospholipase A2 superfamily of signal transduction enzymes. *Trends Biochem. Sci.* 22:1-2, 1997.

Duara, R., C. Grady, J. Haxby, M. Sundaram, N.R. Cutler, L. Heston, A. Moore, N. Schlageter, S. Larson, and S.I. Rapoport. -Positron emission tomography in Alzheimer's disease. *Neurology* 36:879-887, 1986.

Dudley, D.T., L. Pang, S.J. Decker, A.J. Bridges, and A.R. Saltiel.. A synthetic inhibitor of the mitogen-activated protein kinase cascade. *Proc. Natl. Acad. Sci. U S A* 92:7686-9, 1995.

Ellis, R.J., J.M. Olichney, L.J. Thal, S.S. Mirra, J.C. Morris, D. Beekly, and A. Heyman. Cerebral amyloid angiopathy in the brains of patients with Alzheimer's disease: the CERAD experience, Part XV. *Neurology* 46:1592-6, 1996.

Farooqui, A.A., S.I. Rapoport, and L.A. Horrocks. Membrane phospholipid alterations in Alzheimer's disease: deficiency of ethanolamine plasmalogens. *Neurochem. Res.* 22:523-7, 1997.

Frossard, PM, and Lestringant, GG (1995). Association between a dimorphic site on chromosome 12 and clincial diagnosis of hypertension in three independent populations. *Clin Genet* 48:284-287.

Futaki, N., S. Takahashi, M. Yokoyama, I. Arai, S. Higuchi, and S. Otomo. NS-398, a new anti-inflammatory agent, selectively inhibits prostaglandin G/H synthase/cyclooxygenase (COX-2) activity in vitro. *Prostaglandins* 47:55-9, 1994.

Glover, S., M.S. de Carvalho, T. Bayburt, M. Jonas, E. Chi, C.C. Leslie, and M.H. Gelb. Translocation of the 85-kDa phospholipase A2 from cytosol to the nuclear envelope in rat basophilic leukemia cells stimulated with calcium ionophore or IgE/antigen. *J. Biol. Chem.* 270:15359-67, 1995.

Gravitt, K.R., N.E. Ward, and C.A. O'Brian.. Inhibition of protein kinase C by melittin: antagonism of binding interactions between melittin and the catalytic domain by active-site binding of MgATP. *Biochem. Pharmacol.* 47:425-7, 1994.

Griffin, W.S.T., J.G. Sheng, G.W. Roberts, and R.E. Mrak. Interleukin-1 expression in different plaque types in

- Alzheimer's disease: significance in plaque evolution. *J. Neuropathol. Exp. Neurol.* 54:276-281, 1995.
- Han, S.K., B.I. Lee, and W. Cho. Bacterial expression and characterization of human pancreatic phospholipase A2. *Biochim. Biophys. Acta.* 1346:185-92, 1997.
- Hanasaki, K., Y. Yokota, J. Ishizaki, T. Itoh, and H. Arita. Resistance to endotoxic shock in phospholipase A2 receptor-deficient mice. *J. Biol. Chem.* 272:32792-7, 1997.
- Hernandez, M., S.L. Burillo, M.S. Crespo, and M.L. Nieto. Secretory phospholipase A2 activates the cascade of mitogen-activated protein kinases and cytosolic phospholipase A2 in the human astrocytoma cell line 1321N1. *J. Biol. Chem.* 273:606-12, 1998.
- Husain, S., and A.A. Abdel-Latif. Role of protein kinase C alpha in endothelin-1 stimulation of cytosolic phospholipase A2 and arachidonic acid release in cultured cat iris sphincter smooth muscle cells. *Biochim. Biophys. Acta.* 1392:127-44, 1998.
- Huwiler, A., G. Staudt, R.M. Kramer, and J. Pfeilschifter. Cross-talk between secretory phospholipase A2 and cytosolic phospholipase A2 in rat renal mesangial cells. *Biochim. Biophys. Acta.* 1348:257-72, 1997.
- Iadecola, C., F. Zhang, K. Niwa, C. Eckman, S.K. Turner, E. Fischer, S. Younkin, D.R. Borchelt, K.K. Hsiao, and G.A. Carlson. SOD1 rescues cerebral endothelial dysfunction in mice overexpressing amyloid precursor protein. *Nat. Neurosci.* 2:157-61, 1999.
- Ishizaki, J., K. Hanasaki, K. Higashino, J. Kishino, N. Kikuchi, O. Ohara, and H. J. Arita. Molecular cloning of pancreatic group I phospholipase A2 receptor. *Biol. Chem.* 269:5897-904, 1994.
- Itagaki, S., P.L. McGeer, H. Akiyama, S. Zhu, and D. Selkoe. Relationship of microglia and astrocytes to amyloid deposits of Alzheimer disease. *J. Neuroimmunol.* 24:173-182, 1989.
- Iversen, L.L., R.J. Mortishire-Smith, S.J. Pollack, and M.S. Shearman. The toxicity in vitro of beta-amyloid protein. *Biochem. J.* 311:1-16, 1995.

Iwamoto, N., K. Kobayashi, and K. Kosaka. The formation of prostaglandins in the postmortem cerebral cortex of Alzheimer-type dementia patients. *J. Neurol.* 236:80-4, 1989.

Jeandel, C., M.B. Nicolas, F. Dubois, F. Nabet-Belleville, F. Penin, and G. Cuny. Lipid peroxidation and free radical scavengers in Alzheimer's disease. *Gerontology* 35:275-82, 1989.

Johnson, K.A., S.T. Mueller, T.M. Walshe, R.J. English, and B.L. Holman. Cerebral perfusion imaging in Alzheimer's disease. Use of a single photon emission computed tomography and iofetamine hydrochloride I 123. *Arch. Neurol.* 44:165-168, 1987.

Joyce-Brady, M., J.B. Rubins, M.P. Panchenko, J. Bernardo, M.P. Steele, L. Kolm, E.R. Simons, and B.F. Dickey. Mechanisms of mastoparan-stimulated surfactant secretion from isolated pulmonary alveolar type 2 cells. *J. Biol. Chem.* 266:6859-65, 1991.

Kan, H., Y. Ruan, and K.U. Malik. Involvement of mitogen-activated protein kinase and translocation of cytosolic phospholipase A2 to the nuclear envelope in acetylcholine-induced prostacyclin synthesis in rabbit coronary endothelial cells. *Mol. Pharmacol.* 50:1139-47, 1996.

Kanemasa, T., K. Hanasaki, and H. Arita. Migration of vascular smooth muscle cells by phospholipase A2 via specific binding sites. *Biochim. Biophys. Acta.* 1125:210-4, 1992.

Kishino, J., O. Ohara, K. Nomura, R.M. Kramer, and H. Arita. Pancreatic-type phospholipase A2 induces group II phospholipase A2 expression and prostaglandin biosynthesis in rat mesangial cells. *J. Biol. Chem.* 269:5092-8, 1994.

Klinker, J.F., K.L. Laugwitz, A. Hagelucken, and R. Seifert. Activation of GTP formation and high-affinity GTP hydrolysis by mastoparan in various cell membranes. G-protein activation via nucleoside diphosphate kinase, a possible general mechanism of mastoparan action. *Biochem. Pharmacol.* 51:217-23, 1996.

Kundu, G.C., and A.B. Mukherjee. Evidence that porcine pancreatic phospholipase A2 via its high affinity receptor stimulates extracellular matrix invasion by normal and cancer cells. *J. Biol. Chem.* 272:2346-53, 1997.

- Kuo, Y., M. Emmerling, C. Vigo-Pelfrey, T.C. Kasunic, J.B. Kirkpatrick, G.H. Murdoch, M.J. Ball, and A. Roher. Water-soluble Abeta (N-40, N-42) Oligomers in Normal and Alzheimer Disease Brains. *J. Biol. Chem.* 271:4077-4081, 1996.
- Kuo, Y., M. Emmerling, H. Lampert, S.R. Hempelman, T.A. Kokjohn, A.S. Woods, R.J. Cotter, and A. Roher. High Levels of Circulating Abeta42 are Sequestered by Plasma Proteins in Alzheimer's Disease. *Biochem. Biophys. Res. Comm.* 257:787-791, 1999.
- Lambeau, G., P. Ancian, J. Barhanin, and M. J. Lazdunski. Cloning and expression of a membrane receptor for secretory phospholipases A2. *Biol. Chem.* 269:1575-8, 1994.
- Lehtonen, J.Y., J.M. Holopainen, and P.K. Kinnunen. Activation of phospholipase A2 by amyloid beta-peptides in vitro. *Biochemistry* 35:9407-14, 1996.
- Lin, L.L., M. Wartmann, A.Y. Lin, J.L. Knopf, A. Seth, and R.J. Davis. cPLA2 is phosphorylated and activated by MAP kinase. *Cell* 72:269-78, 1993.
- Lindahl, M., and C. Tagesson. Selective inhibition of group II phospholipase A2 by quercetin. *Inflammation* 17:573-82, 1993.
- Lue, L.F., L. Brachova, W.H. Civin, and J. Rogers. Inflammation, Abeta deposition, and neurofibrillary tangle formation as correlates of Alzheimer's disease neurodegeneration. *J. Neuropathol. Exp. Neurol.* 55:1083-1088, 1996.
- McGeer, P.L., M. Schulzer, and E.G. McGeer. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. *Neurology* 47:425-432, 1996.
- McGeer, P.L., and E.G. McGeer. Inflammation of the brain in Alzheimer's disease: implications for therapy. *J. Leukoc. Biol.* 65:409-15, 1999.
- Minami, T., H. Tojo, Y. Shinomura, T. Komatsubara, Y. Matsuzawa, and M. Okamoto. Elevation of phospholipase A2 protein in sera of patients with Crohn's disease and ulcerative colitis. *Am. J. Gastroenterol.* 88:1076-80, 1993.

Morita, I., M. Schindler, M.K. Regier, J.C. Otto, T. Hori, D.L. DeWitt, and W.L. Smith. Different intracellular locations for prostaglandin endoperoxide H synthase-1 and -2. *J. Biol. Chem.* 270:10902-8, 1995.

Murakami, M., S. Shimbara, T. Kambe, H. Kuwata, M.V. Winstead, J.A. Tischfield, and I. Kudo. The functions of five distinct mammalian phospholipase A2S in regulating arachidonic acid release. Type IIa and type V secretory phospholipase A2S are functionally redundant and act in concert with cytosolic phospholipase A2. *J. Biol. Chem.* 273:14411-23, 1998.

Naidu, A., D. Quon, and B. Cordell. beta-Amyloid peptide produced in vitro is degraded by proteinases released by cultured cells. *J. Biol. Chem.* 270:1369-74, 1995.

Nakajima, M., K. Hanasaki, M. Ueda, and H. Arita. Effect of pancreatic type phospholipase A2 on isolated porcine cerebral arteries via its specific binding sites. *FEBS Lett* 309:261-4, 1992.

Nitsch, R.M., J.K. Blusztajn, A.G. Pittas, B.E. Slack, J.H. Growdon, and R.J. Wurtman. Evidence for a membrane defect in Alzheimer disease brain. *Proc. Natl. Acad. Sci. U S A* 89:1671-5, 1992.

Nomura, K., H. Fujita, and H. Arita. Gene expression of pancreatic-type phospholipase-A2 in rat ovaries: stimulatory action on progesterone release. *Endocrinology* 135:603-9, 1994.

Okamoto, T., S. Takeda, Y. Murayama, E. Ogata, and I. Nishimoto. Ligand-dependent G protein coupling function of amyloid transmembrane precursor. *J. Biol. Chem.* 270:4205-8, 1995.

Paris, D., T.A. Parker, T. Town, Z. Suo, C. Fang, J. Humphrey, F. Crawford, and M. Mullan. Role of Peroxynitrite in the Vasoactive and Cytotoxic Effects of Alzheimer's beta-amyloid1-40 Peptide. *Exp. Neurol.* 152:116-122, 1998.

Paris, D., T. Town, T.A. Parker, J. Humphrey, and M. Mullan. Isoform-specific vasoconstriction induced by Apolipoprotein E and modulation of this effect by Alzheimer's beta-amyloid peptide. *Neurosci. Lett.* 256:73-76, 1998.

Paris, D., T. Town, T.A. Parker, J. Tan, J. Humphrey, F. Crawford, and M. Mullan. Inhibition of Alzheimer's beta-Amyloid Induced Vasoactivity and Proinflammatory Response in Microglia by a cGMP-Dependent Mechanism. *Exp. Neurol.* 157:211-221, 1999.

Rogers, J., L.C. Kirby, S.R. Hempielman, et al. Clinical trial of indomethacin in Alzheimer's disease. *Neurology* 43:1609-1611, 1993.

Selkoe, D.J. Amyloid beta-protein and the genetics of Alzheimer's disease. *J. Biol. Chem.* 271:18295-8, 1996.

Serhan, C.N., J.Z. Haeggstrom, and C.C. Leslie. Lipid mediator networks in cell signaling: update and impact of cytokines. *FASEB J.* 10:1147-58, 1996.

Siffert, W, Roszkopf, D, Siffert, G, Busch, S, Moritz, A, Erbel, R, Sharma, AM, Ritz, E, Wichmann, HE, Jakobs, KH, Horsthemke, B. Association of a human G-protein beta3 subunit variant with hypertension. *Nat Genet* 18:45-48.

Sisodia S.S., and D.L. Price. Role of the beta-amyloid protein in Alzheimer's disease. *FASEB J.* 9:366-70, 1995.

Stephenson, D.T., C.A. Lemere, D.J. Selkoe, and J.A. Clemens. Cytosolic phospholipase A2 (cPLA2) immunoreactivity is elevated in Alzheimer's disease brain. *Neurobiol. Dis.* 3:51-63, 1996.

Stewart, W.F., C. Kawas, M. Corrada, and E.J. Metter. Risk of Alzheimer's disease and duration of NSAID use. *Neurology* 48:626-632, 1997.

Suo, Z., J. Humphrey, A. Kundtz, F. Sethi, A. Placzek, F. Crawford, and M. Mullan. Soluble Alzheimer's beta-amyloid constricts the cerebral vasculature in vivo, *Neurosci. Lett.* 257:77-80, 1998.

Thomas, T., G. Thomas, C. McLendon, T. Sutton, and M. Mullan. beta-Amyloid-mediated vasoactivity and vascular endothelial damage. *Nature* 380:168-71, 1996.

Tischfield, J.A. A reassessment of the low molecular weight phospholipase A2 gene family in mammals. *J. Biol. Chem.* 272:17247-50, 1997.

Tohkin, M., J. Kishino, J. Ishizaki, and H. Arita. Pancreatic-type phospholipase A2 stimulates prostaglandin synthesis in mouse osteoblastic cells (MC3T3-E1) via a specific binding site. *J. Biol. Chem.* 268:2865-71, 1993.

Tsunoda, Y., and C. Owyang. The regulatory site of functional GTP binding protein coupled to the high affinity cholecystokinin receptor and phospholipase A2 pathway is on the G beta subunit of Gq protein in pancreatic acini. *Biochem. Biophys. Res. Commun.* 211:648-55, 1995.

Walker, D.G., O. Yasuhara, P.A. Patston, E.G. McGeer, and P.L. McGeer. Complement C1 inhibitor is produced by brain tissue and is cleaved in Alzheimer disease. *Brain. Res.* 675:75-82, 1995.

Wisniewski, H.M., and J. Weigel. Migration of perivascular cells into the neuropil and their involvement in beta-amyloid plaque formation. *Acta. Neuropathol. (Berl.)* 85:586-95, 1993.

Wisniewski, H.M., J. Wegiel, K.C. Wang, and B. Lach. Ultrastructural studies of the cells forming amyloid in the cortical vessel wall in Alzheimer's disease. *Acta. Neuropathol. (Berl.)* 84:117-27, 1992.

Zhu, M., C.H. Gelband, J.M. Moore, P. Posner, and C. Summers. Angiotensin Type 2 Receptor Stimulation of Neuronal Delayed-Rectifier Potassium Current Involves Phospholipase A2 and Arachidonic Acid. *J. Neurosci.* 18:679-686, 1998.

CLAIMS

What is claimed is:

1. A method of modifying vasoactivity by regulating a soluble A β pro-inflammatory pathway.
2. The method according to claim 1, further defined as upregulating the soluble A β pro-inflammatory pathway.
3. The method according to claim 1, further defined as down-regulating the soluble A β pro-inflammatory pathway.
4. A method of treating patients with vascular disease by modifying an intracellular soluble A β pro-inflammatory pathway.
5. The method according to claim 4, wherein said modifying step is further defined as blocking target molecules of the soluble A β pro-inflammatory pathway.
6. A pharmaceutical composition comprising an effective amount of a soluble A β pro-inflammatory pathway regulator and a pharmaceutically effective carrier.
7. The pharmaceutical composition according to claim 6, wherein said soluble A β pro-inflammatory pathway regulator blocks the activity of type I secretory PLA2.
8. The pharmaceutical composition according to claim 7, wherein said soluble A β pro-inflammatory pathway regulator is a non-toxic derivative of oleyloxyethylphosphorylcholine or related compounds.

9. The pharmaceutical composition according to claim 6, wherein said soluble A β pro-inflammatory pathway regulator blocks the activity of cytosolic PLA2.

10. The pharmaceutical composition according to claim 9, wherein said soluble A β pro-inflammatory pathway regulator is one from the group consisting essentially of methyl arachydonyl fluorophosphonate, AACOCF₃, or related compounds.

11. The pharmaceutical composition according to claim 6, wherein said soluble A β pro-inflammatory pathway regulator blocks the activity of enzymes of the LOX family.

12. The pharmaceutical composition according to claim 11 wherein said soluble A β pro-inflammatory pathway regulator is MK-886.

13. The pharmaceutical composition according to claim 6, wherein said soluble A β pro-inflammatory pathway regulator is MAP kinase inhibitor. Selected from the group consisting essentially of p38MAP kinase inhibitors and MEK1/2 inhibitors.

14. The pharmaceutical composition according to claim 6, wherein said soluble A β pro-inflammatory pathway regulator blocks the activity of enzymes of both the LOX and COX families.

15. The pharmaceutical composition according to claim 14, wherein said soluble A β pro-inflammatory pathway regulator is one from the group consisting essentially of

ER-34122, BW-A4C or MK-886 in combination with non-toxic derivatives of NS-398.

16. A diagnostic method including the steps of detecting modification of the soluble A β pro-inflammatory pathway.

17. The diagnostic method according to claim 16, wherein said detecting step further includes detecting any up-regulation of the soluble A β pro-inflammatory pathway.




18. The diagnostic method according to claim 16, wherein said detecting step further includes detecting any down-regulation of the soluble A β pro-inflammatory pathway.

19. A method of modifying inflammatory reactions in microglia and neurons by regulating a soluble A β pro-inflammatory pathway.




20. The method according to claim 19, further defined as upregulating the soluble A β pro-inflammatory pathway.

21. The method according to claim 19, further defined as down-regulating the soluble A β pro-inflammatory pathway.




1/11

Fig-1Fig-2Fig-3




2/11






3/11

Fig-7Fig-8Fig-9




4/11

Fig-10Fig-11Fig-12



5/11





6/11

Fig-16Fig-17Fig-18




7/11

Fig-19Fig-20



8/11





9/11

**Fig-23****Fig-24****Fig-25**

10/11

Fig. 26AFig. 26B

11/11

Fig. 26CFig. 26D

Docket No.
0152.00391

Declaration and Power of Attorney For Patent Application

English Language Declaration

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled
MODULATION OF THE PHOSPHOLIPASE A2 PATHWAY AS A THERAPEUTIC

the specification of which

(check one)

☒ is attached hereto.

☐ was filed on _____ as United States Application No. or PCT International
Application Number _____
and was amended on _____

(if applicable)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate or PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)

Priority Not Claimed

(Number)

(Country)

(Day/Month/Year Filed)

☐

(Number)

(Country)

(Day/Month/Year Filed)

☐

(Number)

(Country)

(Day/Month/Year Filed)

☐

I hereby claim the benefit under 35 U.S.C. Section 119(e) of any United States provisional application(s) listed below:

<u>60/092,570</u>	<u>July 13, 1998</u>
(Application Serial No.)	(Filing Date)
 <u> </u>	 <u> </u>
(Application Serial No.)	(Filing Date)
 <u> </u>	 <u> </u>
(Application Serial No.)	(Filing Date)

I hereby claim the benefit under 35 U. S. C. Section 120 of any United States application(s), or Section 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. Section 112, I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, C. F. R., Section 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application:

<u>PCT/US99/15947</u>	<u>July 13, 1998</u>	<u>pending</u>
(Application Serial No.)	(Filing Date)	(Status) (patented, pending, abandoned)
 <u> </u>	 <u> </u>	 <u> </u>
(Application Serial No.)	(Filing Date)	(Status) (patented, pending, abandoned)
 <u> </u>	 <u> </u>	 <u> </u>
(Application Serial No.)	(Filing Date)	(Status) (patented, pending, abandoned)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.


POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. (list name and registration number)


Kenneth L. Kohn (Reg. No. 30,955)

Amy E. Rinaldo (Reg. No. 45,791)

2 -
Send Correspondence to: Amy E. Rinaldo
Kohn & Associates
30500 Northwestern Hwy., Suite 410
Farmington Hills, Michigan 48334

Direct Telephone Calls to: (name and telephone number)
Amy E. Rinaldo (248) 539-5050

Full name of sole or first inventor <u>Daniel Paris</u>	Date <u>1/23/2001</u>
Sole or first inventor's signature 	
Residence US	
Citizenship FR	
Post Office Address 15210 Amberly Dr., #1125	
<u>Tampa, Florida 33647</u> <u>FL</u>	

Full name of second inventor, if any <u>Terrence C. Town</u>	Date <u>1/23/2001</u>
Second inventor's signature 	
Residence US	
Citizenship US	
Post Office Address 15215 Livingston Ave., #167	
<u>Lutz, Florida 33549</u> <u>FL</u>	

3-00

Full name of third inventor, if any	
<u>Michael J. Mullan</u>	
Third inventor's signature	Date
<i>[Signature]</i>	1/23/2001
Residence	
US	
Citizenship	
US UK	
Post Office Address	
15209 Plantation Oaks Dr.	
Tampa, Florida 33647	

FL

Full name of fourth inventor, if any	
Fourth inventor's signature	Date
Residence	
Citizenship	
Post Office Address	

Full name of fifth inventor, if any	
Fifth inventor's signature	Date
Residence	
Citizenship	
Post Office Address	

Full name of sixth inventor, if any	
Sixth inventor's signature	Date
Residence	
Citizenship	
Post Office Address	